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Abstract
Extracellular vesicles play important and crucial roles in orchestrating and modulating
cellular responses under both normal and diseased conditions. In my thesis work, I studied
extracellular vesicle release from astrocytes during CNS inflammation. Moreover, I studied how
extracellular vesicles can modulate and drive the immune response during active CNS disease.
Extracellular vesicles encompass a heterogeneous group of cell-derived vesicles that have been
found to be important in initiating and directing pathological responses.
In my thesis work, I focused on the characterization and quantification of extracellular
vesicles from astrocytes under normal and inflammatory conditions. As described in chapter three
of my thesis, I developed a semi-quantitative flow cytometry method for analysis of extracellular
vesicles from astrocytes and found that following cytokine challenge in vitro, astrocytes releases
more extracellular vesicles. Additionally, I studied whether astrocyte-derived extracellular
vesicles could be detected in peripheral circulation and if their numbers increased in a mousemodel of multiple sclerosis. Allowing for the potential of astrocyte-derived extracellular vesicles
to be potent biomarkers to monitor disease progression.
Furthermore, I studied whether extracellular vesicles could modulate the immune system
during active disease. As described in chapter four, I found that injection of plasma extracellular
vesicles into animals during the height of clinical disease in a mouse model of multiple sclerosis
induced a relapsing-remitting phenotype that seemed to be driven by an unidentified interaction

Cory Willis – University of Connecticut, 2019

between the blood coagulation factor fibrinogen and CD8+ T cells. Additionally, post-translational
modifications analysis of the proteomic content of plasma extracellular vesicles identified
extensive citrullination occurs on proteins in blood plasma that may be causative in driving the
immune responses observed.
In general, my thesis studies focused on the characterization and effect of extracellular
vesicles from a CNS-cell source and in an animal model of multiple sclerosis.
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Chapter 1. Multiple Sclerosis
I. History of Multiple Sclerosis
Through retrospective analysis of historical medical records, the first observed cases of MS
may have occurred as early as the 14th century (1), and the first definitive case was thought to have
affected Sir Augustus D’Esté, the illegitimate grandson of George III, who chronicled the disease
in his diary from its initial onset in 1822 to his death in 1848 (2, 3). While it is possible that MS
was a relatively uncommon disease before this time, the more likely explanation is that difficulty
in differentiating MS from other contemporary neurological disorders, including neurosyphilis and
paralysis agitans, may have resulted in a delay in a formal description of MS from appearing in
the literature before the early 19th century.
Credit for the initial documentation of the clinical features of MS is usually attributed to
Cruveilhier, a Parisian anatomist, in 1841 or 18421. It was not until 1868 that Jean-Martin Charcot
provided the first, detailed descriptions of the clinical manifestations of MS, established criteria
for its diagnosis, and, for the first time, correlated clinical symptoms with pathological changes:
“Multiple sclerosis is reduced simply to a contracture of the lower extremities, with or
without any spasticity in the upper extremities…In cases of this kind, the present or past
coexistence of some of the cephalic symptoms such as nystagmus, diplopia, disturbances
of speech, dizziness, apoplectiform attacks, special mental symptoms, alone can provide
the basis for a decisive diagnosis. The spinal form of the disease is far from
rare…incidence of the disease will tend to increase as its diagnosis reaches a higher level
of accuracy2.”

1

Cruveilhier J. Anatomie pathologique de corps humain ou descriptions avec figures lithographiees et coloriees des
diverses altrnations morbides don’t le corps humain est susceptible. Paris, France: Bailliere; 1829-1842
2
Charcot JM. Expose des titres scientifiques. Paris, France: Victor Goupy et Jourdan; 1883.
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Over the next 150 years, ideas on the cause and pathogenesis of this disease have developed
the basis for studies on the epidemiology, genetics, pathology, immunology, and neurobiology of
MS. This has moved the study of MS from a system based on exploratory approaches into a
productive discipline grounded in experimental and evidence-based science. As a result, new
questions relating to the definition, nosology, cause, mechanisms, and management of the disease
now challenge several long-standing concepts about this disease.
II. Prevalence and Risk Factors
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central
nervous system (CNS). It is the most common cause of neurological disability in young and
middle-aged adults (4). The incidence of MS is low in childhood and increases with age peaking
between 20 and 40 years of age. There are an estimated 2.3 million people worldwide currently
living with MS (5), however, this number probably underestimates the true global total as
preliminary results from a study by the United States National MS Society on the prevalence of
MS estimate nearly 1 million people in the United states alone are currently living with the disease.
Women have universally been found to be disproportionately affected by the disease, with the MS
prevalence ratio of women to men having markedly increased during the last 100 years (2.3-3.5:1),
indicating a true increase in MS among women but not men (6-9). It has been posited that this
rapid increase probably reflects some yet unidentified changes in the environment or nutrition (10).
However, despite the effect of sex on the prevalence of MS globally, the effect on the clinical
features of MS is not as clear. There is evidence that, in general, women have an earlier onset of
the disease by approximately 2-5 years, a slightly decreased prevalence of being affected by the
primary progressive disease course, and have reduced progression towards disability than men (11,
12).
2

The cause of MS is unknown but current evidence points to an interaction between
environmental and genetic factors in the development of the disease. The timing of exposure to
environmental factors plays a significant role, with childhood and adolescence being the most
critical time frames (13-15). Evidence for these susceptibility time windows comes from elegant
longitudinal migration studies between high- and low-risk regions. Migrants who have been found
to immigrate from a low-risk to high-risk region prior to adolescence adopt the risk of their new
region, whereas migrants who immigrated after adolescence retained the risk of their home region
(16, 17). However, the precise age range cutoff is less clear and the risk of exposure could span a
wider range than was initially thought (18).
Environmental factors known to increase the risk of developing MS encompass (1)
geography, (2) exposure to infectious agents, and (3) gestational environment. Evidence has
pointed to a significant role of the latitude, i.e. increasing distance north or south of the equator,
with an increased incidence and prevalence of MS, however this correlation has been found to be
decreased over the past decades (19-21). There has been no study that has directly and conclusively
linked a single causative infectious agent to the development of MS. In fact, it is thought that MS
can be triggered by several microorganisms in genetically susceptible patients. For example, >99%
of MS patients are seropositive for Epstein-Barr virus compared to 95% in the general population,
and patients with a history of infectious mononucleosis have a higher risk of developing MS
compared to uninfected individuals (12, 22). Lastly, the risk of MS in the northern hemisphere has
been found to depend on the month of birth, with the highest risk for individuals born in May and
the lowest for those born in November (17), which has also been found in animal models of the
disease (23).
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While MS does not have a definitive genetic cause, numerous single nucleotide
polymorphisms have been associated with its development (24). Studies on the contribution of
genetics to the risk of developing MS have examined heritability within families and determined
that risk is lower than would be expected for a genetically inherited disease. MS has been found
to have an overall familial recurrence rate of 20% and shown a concordance rate in monzygotic
twins in 24-30% of cases compared to 3-5% in dizygotic twins. Furthermore, there is no increased
risk for adoptive relatives and besides kinship, the sex of the affected family member and a parentof-origin effect is also known to influence MS risk (25, 26). Given the extensive investigation into
finding a genetic cause for MS, current evidence now points to no marked role for classic genetic
associations with MS. Stronger evidence points to environmental factors as a major driver of
disease susceptibility, opening up the possibility of epigenetics (which some people incorrectly
call “genetics”) as a source of risk for MS (27).
III. Diagnosis and Clinical Forms of Multiple Sclerosis
The diagnosis of MS has traditionally relied upon clinical indicators that have been
developed over decades clinical evidence for associations with MS. The mainstay triad of clinical
tests used for MS diagnosis are MRI, oligoclonal bands in cerebrospinal fluid (OCBs), and clinical
disability. These tests also have a temporal component that is required for the diagnosis of MS.
For instance, brain imaging that identifies white matter lesions must also change in space and time
to support a diagnosis of MS but can also help to eliminate alternative diagnoses that can present
like MS. The most commonly used standard for the determination of a diagnosis of MS is based
on the McDonald Criteria developed in 2001 by the International Panel on the Diagnosis of MS
(28). This was the first formal review of the criteria for MS diagnosis since 1982 (29) and was
developed to facilitate the diagnosis of MS in patients with a variety of presentations, including
4

“monosymptomatic” disease suggestive of MS, disease with a typical relapsing-remitting course,
and disease with insidious progression, without clear attacks and remissions. Previously used terms
in the diagnosis of MS such as “clinically definite” and “probable MS” were replaced with MS,
“possible MS”, or “not MS”. The McDonald Criteria is routinely updated to keep pace with
scientific discoveries and advances in medicine.
Despite the development of an internationally-recognized standard of criteria for the
diagnosis of MS, the focus on the clinical and supporting laboratory evidence from patients that
establishes the diagnosis remains dissemination of sclerotic plaques in both space and time—
disease-related changes have effected multiple regions of the CNS, including the white and gray
matter, brain stem, spinal cord, and optic nerve to form the cornerstone of diagnosis of the disease
(30, 31). The overwhelming majority of patients who develop MS begin with a single episode,
termed CIS. The initial episode tends to involve the optic nerve, brain stem, or spinal cord and
resolve over time. Clinically isolated syndrome is defined as a monophasic clinical episode
evidenced by patient-reported symptoms and objective findings reflecting a focal or multifocal
inflammatory demyelinating event in the CNS, which develops acutely or sub-acutely, with a
duration of at least 24 hours, with or without recover, and in the absence of fever or infection;
similar to a typical MS relapse (attack and exacerbation) (32-34). The concept of CIS is wellestablished in the field and is currently being incorporated into the WHO International
Classification of Disease, version 11 (33, 35). However, not all CIS patients develop MS. For
example, patients experiencing a monophasic, idiopathic inflammatory demyelinating disease that
has all the tell-tale signs of CIS and/or MS, cannot be readily distinguished from patients with
ADEM (36). Therefore, consistent monitoring for emergence of new or exacerbation of existing
symptoms with routine examinations of the CNS for de novo lesion development are vital for a
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diagnosis of MS. If the patient is subsequently diagnosed with MS by fulfilling the diagnostic
requirement of dissemination of plaques in space and time, and ruling out other diagnoses, the
clinically isolated syndrome was that patient’s first attack.
Following the initial attack that brings the patient into the clinic for examination,
monitoring the progression of the disease through MRI scans, oligoclonal analysis, and routine
follow-up examinations by a clinician allows for the establishment of dissemination in time and
place of lesions, detection of inflammatory status, and the development or worsening of clinical
symptoms, respectively. MRI is routinely used to identify the development of new lesions in
patients. That is, episodes affecting separate sites within the CNS have occurred at last 30 days
apart. To determine dissemination in time of magnetic resonance lesions requires one gadoliniumenhancing lesion at least three months after the onset of the clinical event; or a new T2 lesion
compared with a reference scan done at least 30 days after the onset of the clinical event.
Intravenous gadolinium injection during an MRI scan serves two practical purposes: (1) determine
blood-brain-barrier permeability as a result of CNS damage because under normal, non-disease
conditions gadolinium has significantly lower permeability, and (2) gadolinium incorporates into
CNS lesions and provides enhanced contrast indicative of an area of active MS-related
inflammation, meaning demyelination has occurred within the last two or three months.
Longitudinal studies of MRI scans of patients with an initial diagnosis of CIS are predictive for
the development of MS (37).
Oligoclonal bands are an additional way to help narrow down the diagnosis of MS.
Excluding the use of MRI in the diagnosis of MS, the single most consistent laboratory diagnostic
tool used to qualify MS is increased oligoclonal immunoglobulins in the CSF (38). Clonal
expansion of immunoglobulin-secreting B cells and plasma cells in the CNS results in the
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characteristic finding of CSF-specific OCBs, which are bands of immunoglobulins that have been
identified in MS patients (39). Normally, only OCBs made of immunoglobulin G antibodies are
considered, though sometimes other proteins can be taken into account (40-42). Up to 95% of all
patients with MS have permanently observable OCBs (43). In patients with a single demyelinating
episode, detection of intrathecal immunoglobulin synthesis may predict progression to MS (44),
and oligoclonal bands in CSF during the early phase of disease are often associated with a
worsened outcome (45). Although the targets of these immunoglobulins are probably multifaceted,
their presence implies a CNS-restricted immune response. However, some argue that the
specificity of OCBs for MS is poor due, partially, because infections can cause a similar banding
pattern (31). Therefore, a need to identify bonafide biomarkers to track disease initiation and
progression will afford clinicians the ability to therapeutically monitor and target disease activity
and responses to therapies.
MS patients often present with heterogeneous clinical manifestations involving the motor
(i.e., walking difficulties), sensory (i.e., numbness or tingling in various parts of the body), visual
(i.e., blurred and/or double vision), and autonomic systems (i.e., urinary symptoms), and the vast
majority of patients will develop progressive decline in functions associated with speaking,
swallowing, movement, and cognitive faculties. The disease course of any given MS patient is
often unique and highly variable. Despite extensive scientific investigation into the root cause of
MS, no known singular cause of MS has been identified. MS is currently incurable.
The clinical course of MS is unpredictable, varied, and individualized, but dependent on
the type of disease. Patient’s given an initial diagnosis of CIS who then experience at least two
additional relapses are described as having RRMS. RRMS is the most common form of MS,
affecting approximately 85% of people with MS, that is broadly comprised of three stages: (1) pre-
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clinical, (2) relapsing-remitting, and (3) progressive (Figure 1-1A). The initial, pre-clinical stage,
wherein an unknown combination of the previously mentioned environmental and genetic risk
factors trigger the disease, prompts a visit to the clinic.
Patient’s given the initial diagnosis of CIS who then experience at least two additional
relapses are described as having RRMS. Relapses are defined as newly appearing neurological
symptoms that occur in the absence of fever or infections and last for more than 24 hours with
symptoms present over a period of a few days that then spontaneously resolve within a few weeks.
The relapsing-remitting disease phenotype can reoccur every few weeks, months, or even years,
but is highly variable from patient to patient. During the RRMS clinical stage, the accumulation
of these discrete, self-limited episodes (i.e., relapses) can lead to extensive and persistent residual
neurologic dysfunction, such as sensory disturbances, optic neuritis, or disturbances in motor and
cerebellar function. Disability is commonly measured using the Expanded Disability Status Scale
(EDSS) (Figure 1-2). This inflammatory stage may begin sub-clinically and only be evident
through gadolinium-enhanced MRI imaging for active lesions.
Following years or decades of relapsing-remitting episodes and accumulating lesion load
can lead to the progressive clinical stage of the disease wherein neurologic dysfunction
progressively worsens leading to permanent neurological deficits such as: cognitive impairment,
depression, emotional lability, dysarthria, dysphagia, vertigo, progressive quadriparesis, sensory
loss, ataxic tremors, pain, sexual dysfunction, spasticity, etc (46). This is defined as the secondaryprogressive form of the disease and can present with or without super-imposed relapses (Figure
1-1B). Studies (47) have reported on a wide range of the percentage of patients that transition to
this form of the disease, from as high as 70-75% (46, 48) to as low as between 15% (49) and 30%
over long-term follow-ups (35). The latter percentages are lower than previously reported and

8

could reflect changes in the natural history of the disease and the effect of disease-modifying
treatments.
In 15% of MS patients, their disease is progressive from the outset and is therefore termed
PPMS (12, 50). PPMS is described as a gradual but progressively declining clinical course without
the presence of disease remittance (12, 50) (Figure 1-1C). However, 40% of patients experience
superimposed relapses, similar to what is observed in patients with SPMS (51). Patients typically
present with symptoms in their 40s, and there is currently no evidence of gender playing a role in
the incidence rate between men and women. Clinical symptoms tend to be dominated by
dysfunctions of the corticospinal tracts, which leads to patients often presenting with upper motor
neuron syndrome of the legs that gradually worsens to quadriparesis (12, 46). Additionally,
cognitive decline, visual loss, brain-stem syndromes, cerebellar dysfunction, bowel and bladder
dysfunction, and sexual dysfunction are common clinical symptoms associated with the disease
(46). The disease course of PPMS is more aggressive and severe than RRMS. As an example,
using the EDSS score of 6, which would indicate the need for unilateral support to walk at least
100 m, is reached in 7 years in PPMS patients compared to 12 years in SPMS patients (48). Despite
these clinical findings, further exploration of the two-forms of progressive MS (PPMS and SPMS)
have been found to be more similar than different—i.e., the differences between them are relative
rather than absolute (52). Moreover, current pathological data suggest the immune system is only
weakly involved in PPMS which is supported by the wealth of clinical data demonstrating that
PPMS patients do not measurably benefit from any current disease-modifying therapies available
to RRMS patients. PPMS will not be extensively covered throughout the course of this thesis,
instead my focus will remain on the study of relapsing-remitting disease.

9

The standardized definitions of the clinical courses of MS—relapsing-remitting, primary
progressive, and secondary progressive—were proposed in 1996 (51). Despite this, these
definitions are purely descriptive in terms of clinical presentation, incidence rate, and course of
the disease and do not provide any meaningful information or correlation with any underlying
pathophysiology of the disease. Since the standardized definitions have been accepted, the
terminology has evolved to describe the presence or absence of activity, including relapses and
progression and, on MRI, new lesions indicating inflammatory activity and atrophy, which
suggests ongoing neurodegeneration. Being able to link the phenotype of the disease firmly to the
pathophysiology will be crucial for identifying new therapeutic targets for drug discovery to aid
patients with the disease.

10
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Figure 1-1: Clinical disease course in the different types of multiple sclerosis. Representative
graphs of clinical presentations of the different types of MS. Y axis depicting increasing disability;
X axis representing time. (A) Relapsing-remitting multiple sclerosis clinical disease course. (B)
Secondary-progressive multiple sclerosis clinical disease course. (C) Primary-progressive
multiple sclerosis clinical disease course. Figure adapted from the National Multiple Sclerosis
Society: www.nationalmssociety.org/What-is-MS/Types-of-MS
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Figure 1-2: Expanded disability status score for monitoring multiple sclerosis disease
progression. The EDSS was developed by neurologist John Kurtzke as a method of quantifying
neurologic impairment in multiple sclerosis and monitoring changes in the level of disability over
time (53). The scale is widely used in clinical trials and in the assessment of people with multiple
sclerosis (54). Figure is from Singh et al, 2012 (55).
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IV. Pathogenesis of Multiple Sclerosis
The diagnostic hallmark of demyelinating diseases, most notably in MS, is the
development and appearance of sclerotic demyelinated plaques (i.e., lesions) in the white and gray
matter. Four neuropathological patterns of active lesions (e.g., type I-IV) have been described for
MS (Table 1-1) based on the presence or absence of complement and immunoglobulins, apoptotic
nuclei, and/or preferential loss of myelin protein (56), which give rise to the four main types of
MS lesions: (1) reactive, (2) active demyelinating, (3) chronic active, and (4) chronic inactive.
Briefly, reactive and active demyelinating plaques are described as containing dense infiltrates of
macrophages that contain myelin proteins and are predominately identified in the early stages of
the disease. Chronic active plaques tend to have an inactive core with little to no macrophage
infiltration but are surrounded on the perimeter by active macrophages. Finally, chronic inactive
plaques have little to no macrophage infiltration in the entirety of the plaque. The emergence of
these lesions often has a propensity for certain regions of the CNS including: optic nerves,
periventricular white matter, brain stem, cerebellum, and spinal cord (46, 57). It has been noted
that while the predominant type of lesion in a patient may evolve over time (i.e from active to
chronic inactive) that the pattern of all lesions in a patient at any one time are consistently of the
same classification. The development of lesions in MS can be viewed as the end-stage of a complex
process of inflammation, demyelination and remyelination, astrogliosis, and axonal damage and
degeneration. However, despite extensive studies on the pathology of MS lesions, the order of
events as they relate to lesion formation remain elusive. What is known is that CNS tissue damage
in MS is a result of a complex and dynamic interplay between the body’s immune system and
resident CNS cells including, astrocytes, microglia, oligodendrocytes, and neurons.
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There is debate, however, on whether the root cause of MS is extrinsic or intrinsic to the
CNS, i.e., the inside-out (58, 59) or outside-in (60, 61) hypotheses that have dominated the debate
for decades. The “inside-out” hypothesis is based on pathological analysis of the brains of MS
patients which has revealed oligodendrocyte loss and myelin defects and damage without the
presence of active inflammation. The initial event could be the result of oligodendrocyte apoptosis,
through a yet unidentified process or through a viral infection that could cause CNS tissue damage
(30, 62). This loss of oligodendrocytes and generation of myelin debris then results in the
generation of antigens against myelin epitopes and leads to a secondary inflammatory event that
results in further demyelination (58, 59, 63). This is not to be confused with leukodystrophies,
which are a rare group of progressive genetic diseases that leads to abnormal development or
destruction of the white matter (64). The opposing hypothesis of “outside-in” argues the
pathogenesis of MS is centered on the idea that dysregulation of the immune system leads to the
generation of autoreactive cells against components of the myelin-sheath. For example, BBB
disruption can lead to the leakage of the blood-plasma factor fibrinogen into the CNS parenchyma
where it is deposited as insoluble fibrin, which leads to the exposure of cryptic epitopes that can
potently activate the innate immune system (65, 66). In fact, in both MS and EAE, robust fibrin
deposition and microglial activation are observed in the white matter (67), which could act to drive
the necessary signals for CNS-specific T cell infiltration that results in the characteristic formation
of lesions with active inflammation and demyelination (60, 61).
The most salient features of the MS disease pathology are the selective and primary
destruction and loss of oligodendrocytes, axonal degeneration, BBB breakdown, multifocal
inflammation, demyelination, and reactive gliosis (35, 68-70). Although myelin is almost
completely lost in MS lesions, disruption and loss of neuronal integrity (i.e., neurodegeneration)
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is particularly relevant because it is considered the main underlying mechanism of permanent
clinical disability due to the acute loss of axons in new inflammatory lesions in MS patients, which
continues, albeit more slowly, over time in chronically demyelinated lesions (35). Although, it
should be noted that axonal destruction is variable from patient to patient and even between lesions
in the same patient (71, 72).
The formation of lesions is known to occur as a result of inflammation consisting of T
lymphocytes, B lymphocytes, and plasma cells (e.g., macrophages and neutrophils) (30, 31, 35).
Post-capillary venules and veins serve as the initial site for the inflammatory reaction (Charcot
1880), which results in perivenous demyelination that is observed in the initial stages of the
disease. As a result, these lesions then “fuse” to already established demyelinated plaques causing
the lesion border to expand into the surrounding NAWM3. These pathological patterns were first
noted in 1916 by Dr. James Walker Dawson while performing autopsies of brains of people with
MS. These typical perivenous extensions of established lesions have now been retroactively
described as Dawson’s fingers and correlate with a diagnosis of MS (73, 74). The demyelinating
process is also associated with the activation of astrocytes and microglia during active tissue injury,
which results in the formation of gliotic scars (75, 76), which will be covered in detail further on.
MS lesions can, in part, become remyelinated through the recruitment of oligodendrocyte
progenitor cells (OPCs) to the site of injury (58). Areas that have been remyelinated are termed
shadow plaques, which are sharply demarcated inactive lesions that present with axons ensheathed
in uniformly thin myelin (77). However, the extent to which this recovery occurs is highly variable
from lesion to lesion and is considered incomplete (78). Similar perivenous and confluent
demyelinated lesion formation have also been identified in the gray matter of brains of MS patients,
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including the cerebral and cerebellar cortex (79, 80), the deep brain stem nuclei (81-83), and the
gray matter of the spinal cord (84).
During the progressive phase of the disease, the contribution of the peripheral immune
system decreases and immune responses are thought to be confined to the CNS compartment. It is
also during this advanced stage of the disease where the CNS pathology markedly changes from a
focal to diffuse white matter injury, which is associated with wide-spread microglial activation,
diffuse lymphocytic and monocytic infiltrates (75), and increasing cortical involvement. The latter
is thought to be associated with the de novo development of ectopic lymphoid-like follicles in the
meninges (85). These lymphoid-like follicles have been found to contain B cells, T cells, and
plasma cells, with intrameningeal follicles showing robust B cell proliferation (86). The formation
of these meningeal lymphoid follicles in MS patients could represent a critical step towards the
maintenance of humoral autoimmunity and in disease exacerbation, which has led to the targeting
of B cells as an emerging therapeutic target in this stage of the disease (87). In addition, in the
cerebral cortex, widespread subpial cortical demyelination is present and active subpial
demyelination is oriented toward inflammatory infiltrates in the leptomeninges (75, 88).
Inflammation in and around MS lesions is seen in all stages of the disease, thus being present not
only in the brain of patients who died in early (relapsing) MS but also in primary or secondary
progressive MS (89). However, in the progressive forms of the disease, diffuse tissue injury is also
caused by mechanisms other than the compartmentalized immune response, including
degeneration of chronically demyelinated axons (90), damage and dysfunction of astrocytes (91,
92), and microglia activation (93).
The selective perivenous and confluent primary demyelination with oligodendrocyte loss
distinguishes MS from other disease with focal white and gray matter lesions. As examples, NMO,
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focal demyelinated lesions with severe axonal destruction follow a primary astrocyte damage
triggered by specific antibodies against aquaporin-4 (94). In other inflammatory conditions,
primary demyelination may follow virus infection of oligodendrocytes (e.g., progressive
multifocal leukoencephalopathy). In this situation, demyelination initially affects the territories of
single oligodendrocytes, but does not reflect the MS typical perivenous pattern (95). Focal white
matter lesions in other inflammatory diseases or stroke are mainly destructive with parallel loss of
myelin, oligodendrocytes, and axons.
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Table 1-1: Multiple Sclerosis Lesion types and associated pathology. Adapted from (57)
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V. Immune System in Multiple Sclerosis
It is widely accepted that in most forms of MS there is significant involvement of the
immune system as both an initiator of disease and a driver of the clinical relapses in the earliest
stages. Studies utilizing mice and marmoset animal models of disease, particularly EAE, have
identified a fundamental role for the adaptive arm of the immune system in the development of
autoimmunity and the pathogenesis of EAE (96, 97). This has translated to MS patients, as
numerous genetic and pathological analyses of MS lesions and immune cells—i.e. T cells and B
cells—and their products in the blood and CSF of patients has corroborated the findings in lower
vertebrates and has led to the success of clinical trials in MS that target immune molecules or
specific cell types (31, 96, 98, 99). This has reinforced the idea that the immune system, and in
particular autoimmunity, plays a central role in MS and provides strong evidence for the
involvement of particular immune pathways in the pathogenesis of the disease.
Inflammation in MS has been found to only affect the CNS, suggesting that T and B cells
are selectively recruited by CNS-specific antigens. There is evidence that inflammation of the PNS
leads to peripheral neuropathy and the development of spontaneous pain (29, 100), however this
exceeds the scope of this thesis. Despite the discovery of several promising candidate antigens as
causative of MS through both animal and human studies, none of the proposed candidates has ever
been confirmed (101, 102). This aberrant development of T cells that recognize self-antigens leads
to autoimmunity and evokes widespread myelin destruction. Originally, it was posited that myelin
proteins generated as a result of oligodendrocyte destruction were driving the antigen-specific
immune response (30). However, both healthy and MS patients have been reported to have similar
numbers of myelin specific T cells, therefore, a yet known trigger must occur to initiate a loss of
self-tolerance to myelin peptides. Nevertheless, the responses mediated by the circulating
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autoreactive T cells have substantial qualitative differences, most notably that myelin-reactive T
cells from MS patients have a robust memory or activated phenotype, whereas in healthy persons
they have a predominantly naive phenotype (103, 104). This was evidenced in a clinical trial in
which MS patients were treated with an altered peptide ligand of MBP, which in mice seemed to
reduce the pathogenic T cell population and induce a tolerized T cell population, but in humans
resulted in disease exacerbation as a result of an up to 2,000-fold expansion of circulating MBPspecific CD4+ T cells (105). Growing evidence points to a diverse repertoire of specificities
implicated in driving the disease process (30, 106-108) in addition to the observed myelin-driven
response.
For the purposes of this thesis, I will broadly discuss the major T cell subtypes (e.g., CD4+
and CD8+) as they relate to disease pathogenesis and not delve deeper into the nuances and
specifics of these and other immune cell types (e.g., B cells) as CD3+ T cells are the most
numerous lymphocytes in the MS brain in all lesions and at all stages of the disease (74). For
instance, in the majority of MS cases, there is considerable agreement that the disease process
underlying the development of MS starts with increased migration of autoreactive CD3+ T
lymphocytes across a weakened BBB (30) by adhering to the luminal surface of endothelial cells
and migrating into the CNS (46, 109). What initiates the transition of these lymphocytes from
physiological surveillance to a pathological cascade is thought to arise from regulatory defects that
allows these cells to set up an immune response within the brain. This is evidenced by the lack of
regulatory control of lymphocytes in people with MS to effectively carry out suppressive functions
on effector cells, which can result in a breakdown of immunologic self-tolerance to antigens (110).
For example, analysis of CD4+ T cells from MS patients were found to have significantly
increased β-arrestin 1 expression (111). β-arrestin 1 is a key promoter of naïve and activated CD4+
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T cell survival. Therefore, it is thought that these β-arrestin 1 overexpressing cells do not
effectively apoptose on stimulation, increasing the patient’s susceptibility to autoimmunity (111).
Once in the CNS, there is a significant immune response following local T cell reactivation
to self-myelin and non-myelin antigens through the help of APCS, which recruits additional T
cells and macrophages that establish the inflammatory lesions (112). Antigens on the myelin
sheaths or oligodendrocyte soma can be recognized by these cells and cause demyelination and
oligodendrocyte destruction, which results in extensive axonal damage as previously mentioned
in preceding sections (46, 112). Despite MS being thought of as a CD4+ T cell driven disease,
CD8+ T cells have been shown to outnumber all other lymphocytes being widely distributed within
the parenchyma and at the edge of CNS lesions (31, 113). For example, perivascular cuffs at the
edge of active demyelinating lesions in progressive MS contain up to 50 times more CD8+ cells
than CD4+ cells (69, 114), whereas the CD4+:CD8+ ratio in the CSF ranges from 3:1 to 6:1 and
in the peripheral blood is 2:1 in MS patients (69, 115). A portion of the CD8 T cells isolated from
the CNS of patients with MS exhibited evidence of oligoclonal expansion, indicating that these
cells had been amplified via antigen-specific responses (116). In fact, the oligoclonally expanded
CD8 T cells were shown to exist not only in the CNS, but also in the CSF and blood in a small
number of tested patients, where, strikingly, some of the expanded CD8 T cells had persisted in
the blood and CSF for several years (69, 116). Lastly, CD8+ T cells have been observed as
outnumbering CD4+ T cells in MS lesions, evincing the importance of this T cell subtype as a
major driver in disease pathogenesis in MS patients (117). CD4+ T cells, on the other hand, have
been found to be far more concentrated in the perivascular and meningeal cuffs and to a lesser
degree in the lesion environment (69, 89, 118, 119). Other cells can also contribute to the damage
of oligodendrocytes and myelin, including microglia and macrophages through the production of
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pro-inflammatory cytokines and generation of ROS (46, 112). However, the complexity of the
immune-response and the subset of cells, factors, and mechanisms involved, while important,
exceed the scope of my thesis work. What is apparent, though, is demyelination strongly correlates
with disease progression and clinical disability in MS patients. Despite strong evidence for a
critical role of the immune system in disease initiation and development, disease-modifying
therapies do not stop the progression of the disease and the accumulation of permanent
neurological deficits. Therefore, developing therapeutic strategies to dampen the immune response
and lessen the accumulation of irreversible deficits is critical to slowing the course of the disease.
VI. Role of Astrocytes in Multiple Sclerosis
Histological analysis of human brains has revealed that approximately 30% of all glial cells
(i.e., microglia, oligodendrocytes, astrocytes) in the CNS are astrocytes, where individual
astrocytes occupy unique territories demarcated by non-overlapping, star-shaped processes that
extend from the cell soma (120, 121). Astrocytes are diverse cells, which is not unexpected given
the range of functions attributed to these cells in the normal functioning of the CNS. As
components of the neurovascular unit, distal end feet of astrocyte processes form the glia limitans,
which contributes to the maintenance of BBB integrity and forms a secondary barrier that restricts
peripheral immune cells from easily accessing the CNS parenchyma (Figure 1-3). White matter
astrocytes are found to be functionally connected to adjacent astrocytes and to oligodendrocytes
by gap junctions, forming ‘large syncytium-like glial networks that are composed of hundreds of
cells’ (122, 123). Astrocytes are critically involved in the maintenance of neurons through
buffering of extracellular neurotransmitters (124) and secretion of trophic factors (125), regulation
of neuronal synaptic transmission (126, 127), and pruning of synapses (128). Moreover, astrocytes
in the healthy CNS contribute to an anti-inflammatory environment through constitutive low-level
24

secretion of anti-inflammatory factors (129-131). Therefore, changes in astrocyte function as a
result of trauma, disease, or inflammation can lead to drastic alterations in the normal functioning
of the CNS. Growing evidence of astrocyte dysfunction in MS supports this claim and points to an
underlying etiology for astrocytes during disease pathogenesis.
Immune responses in MS involve both the adaptive and innate arms of the immune system,
which induces profound alterations in CNS cells during the progressive stages of the disease.
Under normal, healthy conditions homeostatically active astrocytes carry-out the diverse functions
that have been described above. However, following injury or inflammation (as in the case of MS),
astrocyte reactivity is triggered by oxidative and chemical stressors, pro-inflammatory cytokines,
and damaged-associated molecular patterns, released, in this context, as a result of myelin damage
(132-134). This major phenotypic change in astrocytes is known as “astrogliosis” or “reactive
gliosis,” which will be used interchangeably throughout this section (135).
Astrogliosis is characterized by a hypertrophied morphology and chronic changes to the
gene expression profile, most noticeably the increased expression of GFAP. As a results, reactive
astrocytes can increase the secretion of chemokines and cell adhesion molecules, which can
amplify or activate a peripheral immune response (123). As a result, reactive astrocytes have
recently been categorically defined as “A1” or “A2” according to their transcriptomic profiles,
which is an analogy to the “M1” and “M2” phenotype categories given to macrophages (135, 136)
(Figure 1-4). A1-type astrocytes, which complement component 3 is an identifying marker, are
induced by inflammation, are abundant in MS and other neurodegenerative diseases, and have
been found to secrete a yet to be identified neurotoxin that selectively kills neurons and
oligodendrocytes (136, 137). Transcriptomic analysis of neuroinflammatory A1-type astrocytes
revealed an up-regulation of genes that have previously been shown to be destructive, suggesting
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that A1-types have harmful functions. In contrast, A2-type astrocytes have been found to be
induced by ischemia and show up-regulation of neurotrophic factors and thrombospondins, which
promote survival and growth and synapse repair, respectively (136). This suggests a “helpful”
function of the A2-type astrocytes. However, as the concept of M1/M2 polarization is now
considered an oversimplification of the continuum of phenotypes macrophages can fulfill and has
been abandoned in a formal sense, it is important to consider a similar continuum existing for the
heterogenous populations of astrocytes in both health and disease.
It has been proposed that there are common cellular and molecular features of reactive
astrogliosis (135, 136, 138). This implies that the unique properties of these cells may be specific
to the neuropathology under which they are studied (139, 140). Moreover, the development of
distinctive astrocyte phenotypes may be dependent on the different phases of a pathological
process. Broadly, reactive astrocytes initially increase the production and release of proinflammatory cytokines and ROS in association with hypertrophy and proliferation. This is
followed by a second “recovery” phase, wherein astrocytes promote anti-inflammatory and
neuroregenerative functions through the release of neurotrophic factors (141). Thus, reactive
astrocytes can mount powerful inflammatory responses that drive leukocyte recruitment to the
CNS and aid in the resolution of inflammation through a change in response profiles to an A2type, as well as lead to formation of glial scars that isolate the inflamed area, restrict damage, and
provide structural support (120).
In MS, astrocytes are increasingly recognized as cells that critically and actively contribute
to the development of MS lesions (142, 143). This is in contrast to the previous notion that
astrocytes were only believed to be reactive at a late, post-inflammatory stage by forming a glial
scar (142, 144). In active MS lesions, astrogliosis is a common feature recognizable by
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hypertrophic morphology and reduced process density (142). A hypertophic morphology in
reactive astrocytes is indicative of substantial tissue injury, which is thought to be caused in MS
lesions by oligodendrocyte loss and the resulting disruption of the astrocyte-oligodendrocyte
network (122, 142). As well, reactive astrocytes themselves have been identified as sustaining
substantial damage (145), which can lead to loss of the glia limitans around blood vessels further
increasing the access of immune cells to the CNS (123, 142). Reactive astrocytes have been found
to reside within the active margins of demyelinating lesions, where they can extend into adjacent,
NAWM, which suggests astrogliosis as an early contributor to lesion development (142, 144). This
has been supported by observations in the murine EAE model of MS that astrocytes in nascent
lesions are activated prior to any significant infiltration of immune cells into the parenchyma takes
place (146-148). Interestingly, hypertrophic astrocytes at the leading edge of actively
demyelinating lesions have been found to contain myelin debris (144). This elegant study
demonstrated that myelin-debris uptake by reactive astrocytes induces NF-κB signaling and
secretion of cell-recruiting chemokines. This led to the authors hypothesizing that the uptake of
damaged myelin by astrocytes might be an early trigger that leads to astrogliosis, resulting in an
astrocyte-mediated influx of leukocytes during the very early stages of lesion development (144).
However, this result must be viewed with caution. Observations of expression of MHC class II
and the co-stimulatory molecules CD80 and CD86 by astrocytes within MS lesions supports
myelin phagocytosis by astrocytes as a non-traditional means of antigen presentation of myelin
antigens to T cells. Yet, it has been shown that human astrocytes in culture fail to induce, or
actively inhibit, the proliferation of T cells (149), leaving it either unlikely that astrocytes are
capable of competent antigen-presentation in MS lesions or that the mode of stimulating astrocytes
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to present antigens in myelin lesions is not yet appropriately modeled in vitro (123). This
intriguing possibility is supported by studies from others and warrants future investigation.
While astrocytes are not considered capable APCs, they are known to modulate immune
responses. Reactive astrocytes have been shown to produce chemokines as well as cell adhesion
molecules that are commonly associated with macrophage/microglia and lymphocyte recruitment
into the CNS parenchyma (123, 150). Mouse models have enabled the elucidation of functionally
relevant roles for astrocytes in leukocyte recruitment. For instance, mice with a conditional,
astrocyte-specific gene deletion of CCL2 when EAE-immunized and studied for clinical disease
course were found to develop a less severe EAE disease course, lowered macrophage and T cell
infiltration, and a reduction in astro- and microgliosis (151). Conversely, astrocyte-mediated
recruitment of microglia to demyelinating lesions can also beneficial. This was demonstrated in a
cuprizone-induced demyelination, which does not cause BBB disruption or involve peripheral
immune cell infiltration (152). Astrocytes were genetically ablated in mice treated with cuprizone,
which prevented the recruitment of microglia to sites of demyelination, leading to a delayed
removal of myelin debris, impaired remyelination, and reduced proliferation of OPCs (153).
Therefore, it seems that astrocytes are key in regulating the recruitment and removal of damaged
myelin in MS, which is needed before remyelination can take place (153).
While reactive astrocytes are known to drive a subset of inflammatory and neurotoxic
responses in MS lesions, they may concurrently dampen inflammation and promote
neuroregeneration within lesions. One well studied neurotrophic factor produced and secreted by
astrocytes and neurons in the healthy CNS that may have beneficial effects is brain-derived
neurotrophic factor (BDNF) (154, 155). Deletion of BDNF in astrocytes during EAE resulted in a
more severe clinical course, whereas enhanced BDNF production by astrocytes in the cuprizone
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model enhanced remyelination (156, 157). This has been corroborated in humans as BDNF has
primarily been found in immune cells and reactive astrocytes in MS lesions (158). Furthermore,
the generation of the glial scar following acute inflammation and demyelination in the center of
white matter lesions has a dual role.
Chronic activation of astrocytes is known to develop what is known as the glial scar. The
purpose of the glial scar was originally thought to restrict the spread of inflammatory cells and
limit damage to the surrounding, unaffected tissue by creating a barrier that prevents the spread of
immune cells and toxic levels of extracellular ions, metabolites, and DAMPs (120, 142). While in
some cases this has been considered to restrict tissue regeneration, the glial scar also provides
beneficial features that directly contribute to recovery from CNS insults. For example, glial scars
have been found to support demyelinated axons and restore BBB integrity and function (120, 142).
However, much remains to be understood about the ying and yang of glial scarring to provide
functional and mechanistic insight into what pathways or factors can be targeted therapeutically to
promote a more robust regenerative effect within MS lesions.
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Figure 1-3: Astrocyte endfoot processes form the glia limitans as part of the neurovascular
unit. (A) astrocyte foot processes associate with the basement membrane of the endothelial cell
layer to form the glia limitans to prevent the free movement of cells and small molecules into the
brain parenchyma. (B) Cross-sectional view a blood vessel within the CNS showcasing the
structure of the BBB—astrocyte endfoot processes, endothelial cells, and tight junctions.
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Figure 1-4: Categorization of reactive astrocyte phenotypes lies on a spectrum. (A) Astrocytes
so far have been categorically defined to exist in two distinct reactive states. If this is the case, it
is possible to conceive that they exist as a continuum, with a heterogenous mixed population of
both inflammatory A1-type astrocytes and anti-inflammatory A2-type astrocytes. (B) In another
model that involves alternative reactive-astrocyte polarization states, multiple reactive phenotypes
exist, with ‘n’ number of possibilities. However, it is currently unknown which of these models
best describes reactive-astrocytes, therefore use of single-cell genomic and proteomic analysis
should aid in answering this question in the future. Figure is from Liddelow and Barres, 2017
(136).
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VII. Animal models of CNS Demyelination
Animal models have been vitally important to the study of human diseases. They have
allowed researchers a living tool that can be manipulated to answer many of the unresolved
questions regarding a multitude of human diseases, from elucidating critical mechanisms of the
disease processes, to identifying major cell types involved, and in the development of disease
modifying therapies. In MS specifically, there are three main animal models— experimental
autoimmune encephalomyelitis (EAE), toxin-induced demyelination, and dietary cuprizone
intoxication (discussed below)—used to study how demyelination in the CNS contributes to
disease pathogenesis, remyelination potential, and modeling the progressive form of the disease,
respectively.
EAE was first described in the 1930s when researchers at Rockefeller University
discovered the model as way to study the episodes of paralysis that occasionally occurred
following convalescence of certain viral infections like smallpox and in some circumstances to
vaccinations like rabies (96, 159). Initially, the EAE model was viewed as a way to understand
ADEM, not MS. However, over the past 75 years numerous refinements and variations have been
developed to better model many of the features common to MS: demyelination and axonal damage,
relapsing-remitting episodes of paralysis, and autoreactive T lymphocytes to myelin antigens
(160).
Currently, EAE is the most commonly used animal model to study MS and is best served
as a way to model and study the inflammatory components of the disease. The inflammation,
demyelination, and clinical phenotype associated with EAE varies based on the myelin peptide
used. Common myelin peptides used in the induction of EAE include: peptide residues 35-55 of
myelin oligodendrocyte glycoprotein (MOG35-55); proteolipid protein (PLP); and peptide residues
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1-37 of myelin basic protein (MBP). Once the myelin peptide is chosen, it is then emulsified in
either complete or incomplete Freund’s Adjuvant (with or without mycobacterium tuberculosis,
respectively) followed by an injection of pertussis toxin, which is thought to increase the
permeability of the BBB and sensitize the immune system to the myelin peptide self antigens (161164). The clinical and pathological course of EAE is also highly dependent on the mouse strain
and immunizing peptide used and careful consideration of the disease process under study must
be taken into account (165). For example, EAE induction in C57BL/6J mice using the MOG35-55
peptide results in a well-characterized and highly reproducible monophasic disease course
consisting of an immune response comprised predominately of autoreactive CD4+ T lymphocytes,
demyelination within the CNS, and an ascending paralysis clinical component (164). Despite
replicating many of the common features of the MS disease process, the murine MOG35-55-EAE
does not capture the relapsing-remitting phenotype. Therefore, to study the mechanism(s)
underlying the relapsing-remitting phenotype, a variant of EAE was developed using SJL (Swiss
Jim Lambert) mice immunized against the MBP or PLP peptide (166-168). The disease in this
mouse is characterized by a relapsing-remitting course of paralysis, which can allow for the
assessment of the efficacy of various immunoregulatory strategies in a progressive autoimmune
disease setting (169).
The EAE model in spite of the tremendous insights it has provided as a model of MS is far
from a perfect recapitulation of MS disease as it lacks some salient features of the human disease
(170). One facet of the EAE animal model that has been under growing scrutiny is the
predominance of autoreactive CD4+ T cells in the absence of whereas CD8+ T cells, the latter of
which are known to occur at higher frequency in the human disease and far outnumber the presence
of CD4+ T cells within the CNS compartment, drive disease progression (117). Additionally, due
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to the spontaneous development of demyelinated lesions in this model, studying the processes
involved in remyelination is also challenging if not impossible. In spite of these caveats of the
murine model of MS, EAE has proven useful in the development of drugs to treat the inflammatory
component of MS even if its caveats foreshadow the need for better modeling of the human disease
Currently, four of the sixteen approved MS DMTs were developed following promising results in
this model, including: glatiramer acetate, mitoxantrone, fingolimod, and natalizumab (96, 171).
Future treatments may require developing animal models that better replicate many of the critical
aspects of the human disease are needed. In part, this aspect of animal modeling and the need to
better model human disease, is a component of my thesis studies (see chapter 4).
In the following paragraphs, I will briefly cover additional animal models used in the study
of MS. While these models were not used to generate any results in this thesis, and will not be
covered in depth, they complement emerging concepts for remyelinating therapies and I highlight
the uniqueness of these models for addressing questions that cannot be answered using EAE.
Toxin-induced models of demyelination involves the microinjection of chemical to induce
focal demyelinating lesions in the CNS. Lysophospatidylcholine (lysolecithin) or other toxins
when injected into the spinal cord white matter of mice induce demyelination that also
spontaneously remyelinates. For this reason, chemical lesions of white matter represent models
well suited for study of the molecular and cellular components underlying remyelination following
injury ( 164, 172). Application of the toxin results in the formation of a focal lesion that has a
reproducible and distinct remyelination timeline that is used to study the processes of active
remyelination (172), which is almost impossible to undertake in EAE due to the aforementioned
spontaneous lesion development. However, the lack of an immune component in this model of
demyelination is a major weakness that limits the scope of the of questions the model can answer.
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Another widely used model of CNS demyelination is the dietary neurotoxicant called
cuprizone. This model is used extensively to study PPMS as both share a common feature of
demyelination and remyelination without immune cell involvement (173). Cuprizone is a copper
chelator that was originally used as a model to induce a spongiform encephalopathy (prion-like
pathology) (174). However, for modeling PPMS, cuprizone is administered orally through mixing
with regular rodent chow that reproducibly evokes a robust and predictable CNS demyelination,
which is most noticeable in the corpus callosum (173). The site of injury is both reliable and
consistent and provides a useful tool in studying the events underlying remyelination in the white
matter. However, the exact mechanism of demyelination is not fully understood, but it is known
that the apoptosis of OLs occurs (164).
VIII. Current Disease Modifying Therapies and Future Strategies
The longstanding first line treatment or MS, employed since the early 1950s, has been
corticosteroids. These are still seen as the “war horse” therapy in the treatment of autoimmune
disorders and have represented the standard of care for decades (175, 176). Currently, however,
steroids are only prescribed for acute relapses, which work to reduce the levels of circulating
cytokines by inhibiting production and dampening the activation of the peripheral immune system
(177). This helps to reduce the severity of clinical symptoms associated with relapses and increase
the speed of recovery, but no evidence exists that corticosteroids prevent new relapses from
occurring or influences the progression of the disease (178).
Remarkable advances have been made in the treatment of MS over the last 60 years, with
the predominance of current treatments for MS focusing on modifying the disease course by
diminishing the autoreactive T cell response. There are 15 DMTs approved by the FDA for MS as
of 2017: five preparations of interferon beta; 2 preparations of glatiramer acetate; the monoclonal
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antibodies natalizumab, alemtuzumab, daclizumab, and ocrelizumab; the chemotherapeutic agent
mitoxantrone; and the small-molecule oral agents fingolimod, dimethylfumarate, and
terifluonomide (31, 69). All of the FDA approved drugs have been designed to target some
component of the immune system and virtually every drug impacts the inflammatory relapsing
stage of the disease, leaving the treatment for the progressive forms of MS as an unmet need (69).
It is beyond the scope of this thesis to discuss the relative benefits, risks, modes of action, and
routes of administration of these various medications. It must be noted, though, that all the current
FDA drugs to treat MS have been approved for treating the relapsing-remitting form of the disease
and reduce, to various extents, the likelihood of the development of new white-matter lesions,
clinical relapses, and accumulation of neurologic disability (31). Instead, emerging therapeutic
strategies will be covered and where the trajectory of future therapies is focused.
An exciting and newly emerging therapeutic strategy in the treatment of MS is stem-cell
transplantation. Small-scale studies have been conducted and shown that ablation of the immune
system through chemotherapy and immune-depleting antibodies followed by autologous
hematopoietic stem-cell transplantation may be a highly durable and effective—and increasingly
safe—therapy (31). Longitudinal studies on a small cohort of RRMS patients from a single-group
phase-2 trial revealed an almost full halt to all detectable CNS inflammatory activity and relapse
frequency in the absence of any ongoing DMTs (31, 179). Additionally, 35% of patients showed
sustained improvement in their EDSS score, making this an attractive future therapy for the
treatment of MS (179). In the search for more specific immune-cell targeted therapies, early-stage
efforts to interfere with specific T cell populations that are thought to drive MS, stemming from
data collected from murine EAE experiments, indicates that certain key subsets of helper T cells
are important and are actively being investigated (180, 181). Such approaches may involve specific
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inhibition, clonal deletion, or induction of immunotolerance (31). Despite strong evidence of
involvement of the innate immune system in MS, no large-scale trials have been conducted that
specifically targeted this system for treatment in MS (31). This is likely due to both the protective
and deleterious roles inherent within the system, hampering efforts to appropriately target this
system for therapeutic intervention (31, 182). Nonetheless, due to the pervasive presence of innate
immune cells in and around MS lesions underscores the need for further research.
New strategies to treat MS may require moving beyond the immune system for the
development of targeted therapies. Specifically, an increasing number of studies has focused upon
tissue repair and protection (183). Looking at the repair side, small studies have been conducted
with therapies that promote endogenous remyelination through specific pathways (e.g. antiLINGO-1), however preliminary results have been mixed (184). Further, based on pre-clinical data
using in vitro screens and testing in EAE models, several previously approved FDA drugs (e.g.
clemastine) are being tested for remyelination or myelin protection (31, 185). The transplantation
of neural or OPCs into the brain has also proven to be an effective strategy to promote endogenous
repair in animal models (186), however no well-designed clinical trials involving MS patients has
been undertaken despite the likelihood that promoting endogenous remyelination will prove to be
a more viable and feasible strategy in treating MS (187). Lastly, strategies to target axonal
protection are actively being examined (188). Encouraging results from initial clinical trials testing
a wide variety of drugs has been published or reported, which have lead to several medium-tolarge studies that are currently under way (188). The idea(s) driving this area of active investigation
is that slowing the rate of cerebral or spinal cord atrophy is a feasible goal based on initial findings
to this point, and that a proof-of-concept trial could be undertaken in several hundred people over
a period of a few years (189).
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Currently, there are is only one FDA-approved drugs for therapeutic intervention PPMS
patients. This recently approved agent target B cells and has only been found to attenuate disease
marginally in a subset of patients (190). The current standard of care therapies used by physicians
to treat MS are called DMTs that primarily target immune cells as a strategy to reduce
inflammation and the frequency and severity of relapses, which improves the quality of life of
those with RRMS; whereas SPMS develop a lack of responsiveness to current therapies and PPMS
patients have so-far been refractory to all current DMTs. Thus, DMTs are not an effective strategy
for treating progressive forms of MS (50, 191). Therefore, rigorous investigation into the
underlying cause of disease progression in the etiology of progressive disease in MS (i.e., loss of
regenerative potential) provides potential new avenues for the development of novel therapeutics
to treat patients with the potential to treat the underlying cause in all MS patients.
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Chapter 2. Extracellular Vesicles
I. Brief History of Extracellular Vesicles
The study of extracellular vesicles (EVs) traces its roots back to the late 1940s. The first
observations of EVs were made following preliminary studies addressing the “biological
significance of the thromboplastic protein of blood” (192). In this seminal investigation, Chargaff
and colleagues examined the clotting times of plasma and explored how separation of plasma by
centrifugation at different speeds when they observed that prolonged, high-speed centrifugation
extended the clotting time of the supernatant. They then found that application of the pellet
containing “the clotting factor of which plasma is derived” to plasma could induce a shorter
clotting time. This led the authors to speculate that cell-free plasma contains a sub-cellular factor
that could promote blood coagulation (192). However, it was not for another 20 years, in 1967,
that that subcellular factor was identified through electron microscopy and small vesicles, which
were at that time referred to as “platelet dust”, were identified (193). From the 1970s into the
1980s, more independent observations of extracellular vesicles were reported as being released
from the plasma membrane of rectal adenoma microvillus cells (194), as virus-like particles in
human cell cultures and bovine serum (195, 196), and from seminal plasma (197). It was a
subsequent detailed, ultrastructural study performed in 1983 that examined EVs from
differentiating immature red blood cells and identified a putative mechanism for vesicle release.
Specifically, they observed that vesicle-filled endosomes, termed MVBs, could fuse with the cell
membrane and releasing their vesicles into the extracellular space (198-200). More than a decade
after this finding, Epstein-Barr virus-transformed B lymphocytes were found to secrete antigenpresenting extracellular vesicles that were themselves capable of inducing T cell responses (201).
Building off these salient findings and supplementing with the discovery of EVs containing RNA
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and proteins, there has a resurgence in interest in determining whether EVs are significant
mediators of cell-to-cell communication and their contributions in pathological settings (202, 203).
Due to the increasing data on EV structure, function, and content, a coalition of EV
researchers formed the International society of Extracellular Vesicles (ISEV) in 2011 with the
expressed aim to unify the nomenclature and methodologies of EV research. Hence, the journey
of EVs from “platelet dust” to significant mediators of cell-to-cell communication has led to the
investigations of EVs as potential biomarkers in an array of diseases, as initiators and facilitators
of disease pathogenesis, and as therapeutic tools. My thesis work tackles two important areas of
EV research: (1) my initial work aimed to identify a cell-specific marker of EVs, which is currently
lacking in the field, for potential use as a diagnostic monitoring tool of disease activity in MS, and
(2) elucidate the immunomodulatory function(s) of plasma EVs during disease exacerbation, an
area of active research. There is still much to be learned, but the future is bright for these small
vesicles.
II. Extracellular Vesicle Subtypes
The traditional view of how extracellular vesicles contribute to cellular communication is
that cells secrete a limited repertoire of proteins as cargo in EVs through the secretory pathway
[e.g., endoplasmic reticulum to Golgi to plasma membrane]. Cells then can release and/or take up
small molecules through transport channels and additional post-Golgi secretory vesicles, which
has collectively been termed the secretome (204, 205). However, it has become increasingly clear
that this is an outdated view of cellular communication. Newer insights into mechanisms of cellto-cell communication, vis-a-vis secreted vesicles, is bringing to light a more complex and diverse
process than ever previously thought. There is now compelling evidence that nearly all cell types
are capable of releasing EVs. EVs come in a diverse range of sizes, collectively referred to as
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extracellular vesicles, but with subclasses within the category of EVs having been given specific
labels, such as exosomes (see below). It is also clear that use of EVs inter-cellular communication
is not an adaptation limited to higher organisms as this process of EV-mediated communication is
evolutionarily conserved from bacteria to plants to humans (206-208). That EVs are no longer
thought of as simply ‘cellular dust,’ EVs are now seen as key players in intercellular and even
interorganismal communication. As a result of these findings, one of the main interests in the field
is to elucidate the capabilities of EVs to exchange biological materials between cells—RNA,
miRNA, proteins, and lipids—and further understand their role as signaling in the maintenance of
normal cell homeostatic processes and also in the context of disease or pathological states (209211).
Currently, the field of EV biology has settled on using the generic term ‘extracellular
vesicles’ to refer to all secreted membraneous vesicles (212). A large amount of work has been
dedicated to understanding the protein and lipid components of EVs, as well as their physiological
relevance, and this is an active and rapidly expanding field of study (204). We now know that the
generic term ‘EV’ encompasses a highly heterogenous collection of membrane-bound carriers with
complex cargoes which are present in a myriad of biological fluids, including: saliva, urine, nasal
and bronchial lavage fluid, plasma, serum, and seminal fluid (209, 213-216). Whereas in years
past there have been a myriad of labels for different EVs, insights into the biogenesis of EVs using
electron microscopy and biochemical markers has resulted in broadly dividing EVs into two main
categories: exosomes and microvesicles (217-219).
Exosomes are small, nanosized vesicles roughly 30-150 nm in diameter (220) that are
thought to be released by all cells and are present in many and perhaps all biological fluids (213,
214, 221, 222). The nomenclature of ‘exosome’ was initially used to describe vesicles of an
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unknown origin released from a variety of cultured cells and carrying 5’-nucleotidase activity
(223). This term was then subsequently adopted to define membrane vesicles (30-150 nm in
diameter) released by reticulocytes during differentiation (200) but has since been extended to
identify all vesicles released from cells that fit within this size range. Exosomes have been
morphologically characterized as having a ‘cup shaped’ appearance when visualized by
transmission electron microscopy (TEM) (224). However, whether this is a unique feature of
exosomes or simply an artifact due to extensive sample preparation for TEM is not currently
known (225). With regard to their biochemical composition, exosomes have a phospholipid bilayer membrane containing relatively high levels of cholesterol, sphingomyelin, ceramide, and
detergent-resistant membrane domains (i.e., lipid rafts) (226-229). Of particular interest to
understanding diseases and the contributions of exosomes to disease processes, exosomes are
thought to retain cell-type specific markers of the cell of origin. This feature offers the potential to
allow for identification of the cellular source(s) of exosomes in complex biological fluids. More
broadly, exosomes can been identified by presence of the tetraspanin protein CD63, specific lipid
raft-associated proteins, including flotillin-1 as well as internal, endosomal markers such as Alix
and TSG101 (230).
“Microvesicles” (MVs) is a term used to specify extracellular vesicles that are released
from the plasma membrane during episodes of cellular stress. This subclass of EVs were initially
thought of as ‘platelet dust’, having first been described as subcellular components that originated
and were released from platelets in plasma and serum (193). Although MVs have mainly been
studied for their role in blood coagulation, more recently, these EVs have been reported to play a
role in direct cell-cell communication among various cell types. MVs have been identified in many
of the same biological fluids where exosomes have been found. MVs are defined over a wider
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range of sizes than exosomes—50 to 500 nm in diameter, with some being up to 1 µm—with
phosphatidylserine (PS) often mentioned as a typical marker (228, 231). However, the use of PS
as a marker of MVs is questionable at best given the significant number of MVs that do not express
PS (232, 233).
Despite efforts to categorize extracellular vesicle subtypes based on specific sizes,
morphology, and/or molecular markers, the extensive overlap in size classes, the similar ities in
vesicular morphologies, as well as the variable compositions have ultimately limited our ability to
devise a more precise nomenclature for EVs (234, 235). In fact, due to increasing evidence pointing
to a significant overlap in the characteristics previously thought to uniquely identify exosomes and
MVs suggests that a future iteration of EV nomenclature may offer a spectrum of vesicle types
with overlapping and unique properties present in all biological fluids (224). However, great
strides have been made in developing isolation and characterization methods that will allow for a
more thorough description of the respective functions of the different types of EVs, which will
hopefully lead to the establishment of a suitable classification and terminology system in the near
future (205).
III. Extracellular Vesicle Biogenesis and Release
There are multiple mechanisms which drive the biogenesis of EVs. Each specific
mechanism represents a significant determinant of the type of EV formed. One essential element
of EV generation is that lipid curvature must be induced to form either an inward-budding vesicle
within the endocytic system (i.e. exosomes) or an outward-budding vesicle at the plasma
membrane (i.e. microvesicles) (204) (Figure 2-1A). A diverse array of mechanisms has been
described for exosome biogenesis, however the best characterized mechanism involves the
recruitment of the endosomal sorting complex required for transport (ESCRT) machinery to
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ubiquitinated proteins in the early endosome (Figure 2-1B). The ESCRT machinery is comprised
of four protein complexes—0, I, II, III—and critical accessory proteins (Alix, VPS4, and VTA-1)
that act in concert to facilitate the formation and packaging of intraluminal vesicles (ILVs) (236).
It should be noted that the ESCR-III complex is essential for the proper biogenesis of exosomes
as it forms spirals that induce inward budding and fission of vesicles to form MVBs (237-239). A
recently described alternative pathway of exosome formation involves the synthesis of ceramide
as a mechanism to induce vesicle curvature and budding, which explains the observations of
preferential loading of certain ceramide-dependent cargoes into ILVs of the MVB (240, 241). A
third mechanism of exosome biogenesis has also been proposed which involves the tetraspaninmediated organization of specific proteins, such as the amyloidogenic protein premelanosome
protein (PMEL) (242, 243). The observation and identification of multiple mechanisms of
exosome biogenesis has only served to highlight the complexity of this biological process.
Therefore, in the following paragraphs I want to broadly cover what is both known and unknown
regarding exosome generation in order to put into context how much is left to discover about this
process.
Initial studies into the ESCRT machinery driving exosome biogenesis identified an
essential set of protein complexes that were thought to progressively execute stages of ILV
formation. More recent data, however, suggest that not all of these components of the pathway are
essential to EV biogenesis, with some complexes involved in the early stages of the biogenesis
being more critical than later ones (204, 209, 244). The paradoxical nature of this is revealed when
select ESCRT-0 and -I proteins are knocked-down and found to result in decreased exosome
release. In contrast, knockdown of ESCRT components involved in the later stages of EV
biogenesis had no effect or in fact were found to increase exosome release from cells (209, 244).
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Further investigation applying simultaneous knockdown of multiple ESCRTs determined that
ILVs are continuously formed however it should be noted that with knockdown fewer ILVs were
formed, that these ILVs had an abnormal size, and these ILVs did not contain epidermal growth
factor receptor (EGFR), a classic ubiquitinated protein sorted by ESCRTs to ILVs (245). Despite
a growing awareness of the diverse and complex machineries involved in exosome biogenesis, it
is not known whether these proposed pathways are distinct or interdependent (246). For example,
the currently proposed ceramide mechanism only accounts for the membrane curvature function
but does not explain cargo sorting (204). Additionally, it could be just as likely that cargo-sorting
mediated by the ESCRT machinery could work in tandem with ceramide-induced lipid curvature
to form and load exosomes. It is also possible that compensatory and redundant mechanisms may
exist to allow for a low-level of constitutive ILV formation, even in the absence of specific
complexes (204). This would also support an argument for a different process that could account
for stress- or injury-induced changes in exosome production or content and release. Growing
evidence of the diverse mechanisms at play in ILV formation highlights the ever-growing
complexity of this process and further state-of-the-art techniques are needed to resolve these
issues.
Despite abundant research into the mechanisms involved in exosome biogenesis, the
mechanisms of microvesicle biogenesis (i.e. direct budding from the plasma membrane) are even
less well known (204). Interestingly, one identified mechanism of MV generation involves the
recruitment of the same ESCRT machinery involved in the formation of ILVs in the MVB, and in
viral budding (Figure 2-1C). Recruitment of the ESCRT-III components involved in promoting
the negative curvature needed to form and pinch off exosomes also performs the same function for
generating MVs from the plasma membrane (236-239). This was observed in a system wherein
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the adaptor protein arrestin domain-containing protein 1 (ARRDC1) was capable of recruiting the
ESCRT proteins TSG101 (ESCRT-I) and VPS4 (accessory protein) to the plasma membrane
(247). It should also be noted that vesicle budding can result from disruption or injury to the plasma
membrane, which acts as a mechanism to repair the damaged membrane (248, 249).
Ceramide has also been found to be involved in MV generation. Alterations in the content
of ceramide on the outer leaflet as a result of acid sphingomyelinase activation can induce
membrane curvature and trigger MV release (250-252). There do not seem to be localized areas
dedicated to MV release, as the shedding of vesicles has been shown to occur at multiple areas
across the plasma membrane, including microvillar protrusions of intestinal epithelial cells (253)
and from cilia (254).
The release of EVs by cells is dependent on the diverse cellular mechanisms involved in
their mode of biogenesis (209). The budding and release of MVs occurs when membranous
protrusions pinch off from the cell surface. Exosomes, on the other hand, derive from the endocytic
system and are released when MVBs fuse with the plasma membrane. However, MVBs can
undergo an alternate fate by fusing with lysosomes leading to the degradation and recycling of
their protein, nucleotide, and lipid contents. Since exosomes are known to contain growth factors
and other signaling molecules, the fusion of MVBs with lysosomes could be an internal control
mechanism to prevent autocrine signaling from occurring. Similarly, fusion of MVBs with the
plasma membrane leading to the direct release of exosomes could promote both autocrine and
paracrine signaling (209, 244). Based on current evidence, the intracellular fate of MVBs to
degrade or release could be influenced at numerous steps. These steps include the intracellular
transport of MVBs along microtubules to the plasma membrane, creation of docking sites at the
plasma membrane, or recruitment of soluble NSF attachment protein receptor (SNARE) proteins
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that mediate fusion with either lysosomes or the plasma membrane. Additionally, the targeting of
MVBs to lysosomes has been shown to occur as a result of autophagosomes-MVB fusion.
Numerous molecular regulators have been implicated in exosome release including multiple
molecules thought to be involved in MVB docking (e.g., GTPases Rab27a, Rab27b, Rab35, and
RalA (255-257), the cortical actin regulator cortactin (258), as well as the fusion regulator
synaptotagmin-7 (259), highlighting the diverse cellular components involved not only in the
biogenesis but also release of EVs (Figure 2-1C). Understanding the factors and components
intrinsically necessary for EV release will not only help to elucidate fundamental mechanisms of
intercellular communication in development and homeostasis, but would be expected to provide
important insights into cellular mechanisms of disease.
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Figure 2-1: Molecular Machineries involved in EV biogenesis and release. (A) Biogenesis and
release of microvesicles and exosomes from the cell. (B) Molecular machineries known to be
involved in the biogenesis of exosomes. (C) Molecular machineries and proteins known to be
involved in the release of microvesicles and exosomes from the cell. Figure adapted from Colombo
et al, 2014 (209).
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IV. Extracellular Vesicles and Neurodegenerative Diseases
Intercellular communication in neurodegenerative diseases is an active and growing area
of research with potential for both biomarker and therapeutic development. The complex
molecular events disrupted within a cell in a neurodegenerative disease cannot be overlooked for
the potential impact on EV biology. Increasing numbers of studies point to secreted factors
released from these cells having effects on neighboring or even distant cells that further support
potential roles for EVs in neurological and neurodegenerative diseases. Therefore, in this section
I will focus on our current understanding on the neurobiology of EVs as contributors and possible
drivers of neurodegenerative disease pathogenesis.
A vast majority of cellular communication happens through the extracellular space and is
viewed as an ideal ‘compartment’ for therapeutic intervention—to modify the disease—or to probe
and sample for diagnostic assessment of disease progression (260). Over the last decade numerous
mechanisms of cell-to-cell communication in neurodegenerative disease have been studied with
exosomes and EVs consistently emerging as common players. Many of the mechanisms under
study, including the clearance and disposal of toxic byproducts and molecules and the cell-to-cell
transmission of inflammatory factors and aggregated or misfolded proteins involve some facet of
EV function (260, 261). Despite most of these findings having been achieved in vitro, the
advancements in the field have led to a greater understanding of the role of EVs in various
neurodegenerative disease processes.
Many of the most common and well-studied neurodegenerative diseases are now known to
have an EV component to them. Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic
lateral sclerosis (ALS), Huntington’s disease, multiple sclerosis (MS), and the family of prion
diseases all now have EV-mediated processes associated with them. I will broadly cover some of
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the functions of EVs in each of these diseases with a central focus on what we know about EVs in
MS. Additionally, to provide clarity in the descriptions and due to the disparate and, as of yet,
unresolved categorical labeling of exosomes and microvesicles in the literature, I will refer to both
classes as ‘extracellular vesicles’ rather than switch between exosome and microvesicle.
Many neurodegenerative diseases are now considered proteinopathies: diseases in which
the release and deposition of toxic proteins contribute to pathogenesis. As a corollary of this, it is
not surprising that EVs are now also being implicated as mechanisms of protein transport in these
diseases. For example, in prion disease, evidence for an EV-mediated propagation of prion proteins
has been identified wherein abnormal PrP are associated with EVs released from (PrP) expressing
cells in vitro (262). Validation of this cellular mechanism comes from the in vivo identification of
abnormal PrP associated with EVs from the CSF of sheep (222). Together, these findings support
the established prion hypothesis which posits that an unknown trigger results in the aberrant
protein confirmation of native PrP. This leads to transformed cellular conformation, PcP, to
misfolded PrP proteins which then ‘transmit’ their misfolded state to additional ‘naive’ proteins.
This cascade of protein misfolding results in aggregates of oligomers that form fibrils that trigger
a chain-reaction of refolding and aggregation that can spread to other cells and results in tissue
destruction and neurodegeneration (263, 264). Moreover, the prion hypothesis now places EVs as
a vital element in that process of dissemination PrP.
Similarly, in the proteopathies of Alzheimer’s and Parkinson’s diseases, a role for EVs in
the progressive accumulation of misfolded proteins has also been identified. In AD, β-amyloid
(265-268), tau (269-272), and in PD, α-synuclein (273-275), are known to accumulate in neural
tissue and then spread with pathology often spanning neuroanatomically connected regions (260,
264, 276). EV-associated hyperphosphorylated misfolded tau has been identified in the CSF of

53

AD patients (277). This supports in vitro studies which have reported EV-associated tau capable
of being transmitted trans-synaptically via extracellular release. This EV-mediated transfer of tau
highlights a potential novel mechanism for the progression of neurodegeneration via EV
distribution of mutant tau within the brain of AD patients (260, 270, 271). Although a similar
process has been suggested for PD, where α-synuclein has been identified in association with EVs
(278, 279), the role of EVs in the spread of mutant α-synuclein is still a matter of considerable
debate. Nevertheless, the key observation that EVs can accelerate aggregation of α-synuclein (274)
points to one possible mechanism linking EVs to PD as well.
EVs have also been implicated in the pathogenesis of ALS and HD. In ALS, misfolding of
the Cu/Zn SOD1 into aberrant conformations has been pinpointed as a critical and central event
that drives the familiar and sporadic forms of the disease. The involvement of EVs in this process
was discovered utilizing in vitro neuron and astrocyte cell-based models of the disease. Neurons
expressing the mutant human form of SOD1 were shown to release the mutant protein in
association with EVs into the extracellular space (280) resulting in the transmittance of this
pathogenic trait to other neurons whereby it can propagate further misfolding and spreading of
SOD1 (281). Astrocytes expressing a mutant version of the SOD1 protein have also been shown
to release mutant SOD-1-in EVs and that SOD1 mutant astrocytes are known to be selectively
toxic to motor neurons, the transfer of the mutant SOD-1 from astrocyte-derived EVs to then be
detected in wildtype motor neurons again points to a pathogenic role of EV-mediated transfer of
toxic proteins between cells (282). Any pathogenic role of EVs in HD is currently limited,
however, evidence for cell-to-cell propagation of mutant Huntingtin (mtHtt), much like what has
been reported to occur in PD, is supported by data from in vitro models of the disease. (283).
Additionally, injection of human mtHtt-loaded EVs into the CNS of newborn, wild-type mice has
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been shown to be sufficient to evoke Huntington disease-like symptoms and pathology in these
wildtype recipient animals (283).
The contribution of EVs to MS pathology differs significantly when compared to the role
of EVs in neurodegenerative diseases with respect to the wide body of literature on the role of EVs
in primary proteopathies. Whereas growing evidence supports a role for EVs in the transfer of
toxic proteins to target cells in ALS, PD, and HD that drive pathology, EVs in MS are thought to
have a role in modulating the immune responses that drive disease progression. Specifically, given
the central role of the immune system in MS, a role for EVs in regulating the activation of T cells
and also facilitating the transendothelial migration of leukocytes across the BBB into the CNS has
been reported (284).
In 1989, Scolding et al. were the first to demonstrate that recovery of oligodendrocytes
from an injury involved the release of membrane-attack complexes enriched with complement
proteins and galactocerebroside vesicles. These complexes emanated from the surface of viable
cells and formed vesicles that could be isolated from the CSF of patients with suspected MS
(compared to normal controls and patients with structural CNS damage) (285). These findings
from Scolding’s work now support a prevailing hypothesis that repeated complement-dependent
injury of oligodendrocytes, and their myelin membranes, contributes to the immunopathogenesis
of MS. These seminal findings also provide a new perspective on how EVs released from
oligodendrocytes during complement-mediated injury can protect these fragile cells from more
extensive damage or dysfunction (285).
While in many instance, the cellular source of EVs are not well defined, it has been shown
through in vitro studies that brain endothelial cells are capable of releasing EVs that can activate
CD4+ and CD8+ T lymphocytes through the targeted expression of β2-microglobulin, MHC II,
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CD40, and ICOSL (i.e. inducible costimulator-ligand) (286). Given the critical effector functions
of CD4+ and CD8+ associated with the pathology of MS, these data point to a potential pool of
circulating EVs derived from endothelial cells with immunomodulatory potential that can drive T
cell activation in MS. This notion is supported by two findings: (1) that brain microvascular
endothelial cells (BMEC) treated with plasma from MS patients results in increased release of EVs
compared to treatment with normal plasma, and (2) elevated endothelial EVs are found in the
plasma of MS patients (287, 288). Additionally, in conjunction with endothelial-derived EVs,
platelet-derived EVs collected from MS patients have been found to increase the permeability of
endothelial layers using in vitro models. These complementary findings suggest that EVs released
from cells in vivo can work to disrupt the BBB and promote disease in a manner other than directly
on T cells. Increased BBB permeability is a widely observed feature of MS pathology (289-291).
Furthermore, there is also evidence that plasma EVs are capable of interacting and forming
complexes with monocytes that can then induce their activation. Collectively, the findings of these
studies point to EVs in potentially important roles mediating the transendothelial migration and
activation of inflammatory cells in MS (292).
EVs derived from several cell types known to be involved in MS have also been implicated
in disease progression and pathogenesis. In a relapsing-remitting EAE animal model, analysis of
the CSF reported a significant increase in the concentration of myeloid-derived EVs. This was also
closely associated with the clinical disease course and were found to propagate inflammatory
signals; supporting a pathogenic role for these EVs in the disease (293). These findings in an
animal model of MS parallel observations of increased myeloid-derived EVs in the CSF of
relapsing-remitting patients compared to healthy control subjects (293). Interestingly, mice
deficient for acid sphingomyelinase (aSMase), which controls the budding of EVs, have been

56

reported to be resistant to induction of EAE. However, these findings must be viewed in their
appropriate context since aSMase mice are known to have defects in other processes relevant to
developing EAE and so this finding, while potentially interesting, does not explicitly implicate
EVs in the altered phenotype of these mice (293). Nevertheless, accumulating evidence suggests
manifold roles for EVs in the inflammatory processes during MS pathology. Future studies will be
necessary to decipher whether and how EVs participate in the interplay between inflammation and
tissue degeneration in demyelinating diseases like MS.
V. Extracellular Vesicles as Biomarkers in Neurodegenerative Diseases
The identification of neurodegenerative disease related proteins in EVs has led to growing
interest in their use as putative biomarkers to monitor disease progression and as a minimally
invasive means to monitor therapeutic effects of treatments. EVs can be readily isolated using noninvasive techniques from multiple biofluids, including: urine, blood, and CSF; facilitating their
use as clinical biomarkers (294-296). In moving towards the adoption of EVs as clinical
biomarkers, the ability to objectively assess the diagnostic potential of EVs must be rooted in
sound and reproducible standards for their use in identifying and monitoring the course of a given
disease. However, despite the accessibility of these biofluids, current findings have been less than
clear. For example, studies investigating quantitative differences in neurodegenerative disease
related proteins in total CSF or associated with EVs purified from CSF have led to contradictory
results in both AD and PD (297-299). In AD, an attempt at quantifying the disease-related protein
hyperphosphorylated-tau in association with EVs found a significant increase in patients with mild
forms of AD compared to controls (277). Despite this promising finding suggesting the
measurement of tau phosphorylation in EVs could be employed as a clinical biomarker of the
disease, moderate or severe forms of the disease do not show similar phosphorylation levels,
57

limiting the use of this approach (260). It has been suggested that one possible explanation of these
disparate results is that the elevated levels of phosphorylated tau in EVs could be specific for the
stage of the disease rather than the entire pathological process (260). With regard to PD, similarly
contradictory results have also been reported in the literature. As an example, a recent report
showed an increase in α-syn in EVs from PD patients while a different study from another group
observed no variations in EV α-syn content (300, 301). Again, this discrepancy has been attributed
to technical differences between lab, inherent difficulties in EV isolation, as well as the natural
heterogeneity of these human patient populations (260).
EVs are known to be abundant with proteins and peptides. Therefore, recent initiatives
have encouraged use of large-scale methodologies to analyze the proteinaceous EV content (e.g.
LC-MS/MS and SILAC). For example, analysis of circulating EVs from healthy and PD patients
using mass-spectrometry identified the enrichment of syntenin 1, a regulator of exosome
biogenesis, in EVs from PD patients (301). Similarly, in EVs purified from control and prioninfected cells, miRNA analysis revealed a distinct set of nine miRNAs enriched in EVs from prioninfected cells, identifying a potential molecular signature that can be used to monitor the
pathological process (302). However, caution must be used in evaluating the relevance of these
“molecular signatures” as identifiers of the disease process. Instead, it may be more appropriate to
establish a patient signature of changes in disease-related proteins in EVs. This would allow for
the development of more precise diagnostic tools that can be applied to a specific patient’s disease
course, rather than treating changes in disease-related proteins as applicable to all patients, which
could lead to more directed therapeutic strategies to combat disease progression.
The widespread reporting of EV “counts” coupled with clinical evaluation of MS status
together as biomarker of disease activity and progression was first suggested in 2001 by Minagar
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et al. The results from their study revealed that concentrations of CD51+ endothelial-derived EVs
(EEVs) were higher during relapses than in remission, while a separate population of CD31+ EEVs
were only higher during relapse when compared to healthy controls (287). Given these findings,
they proposed that CD51+ EEVs were associated with chronic inflammation due to erosion of the
endothelium of the BBB coupled with subendothelial matrix exposure, whereas CD31+ EEVs
reflected acute endothelial damage. Additionally, the authors also described a concordance
between CD31+ EEV counts and gadolinium enhancing MRI lesions, as well as making the claim
that this population of EVs were “as sensitive as gadolinium-enhanced MRI” for detecting disease
activity, and that a decrease in vesicle count could be indicative of negative MRI findings (287).
Despite these bold claims, the findings could not be replicated in vitro and were criticized for being
premature speculation not supported by sufficient evidence (303). However, the findings pointed
to the presence of factors within the plasma of MS patients that could potentially be used to monitor
not only disease progression but also response to therapy (304).
Within the same line of research, two additional studies investigating the use of EEVs as
biomarkers in MS were published over the next five years. The first publication explored whether
CD54+ and CD62E+ EEVs were capable of binding to leukocytes in vitro as well as in whole
blood from MS patients and healthy controls (292). The main conclusions drawn from the study
was that CD54+ EEVs were able to: (1) form complexes with monocytes, (2) complex formation
was TNF-α-dependent, and (3) monocytes were activated (292). The authors also found that the
presence of CD62E+ EEV-monocyte complexes were increased during periods of disease
exacerbation compared to periods of disease remittance while the number of CD54+ EEVmonocyte complexes remained unchanged. This suggested that the use of CD62E+ EEVs would
be a better biomarker for monitoring MS disease activity (284). The second study explored the use
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of free CD54+ and CD62E+ EEVs as biomarkers of disease relapse and remittance. To do this,
plasma from healthy patients, patients in disease remittance, and patients experiencing disease
exacerbation were applied to BMVECs in vitro and counts of these EEV sub-populations
measured. Analysis found that CD54+ and CD62E+ EEVs from patients experiencing active
disease were significantly higher compared to healthy patients and patients under disease
remittance. Additionally, these two populations were higher than the CD31+ EEV population
identified previously, indicating that these populations of EEVs may be a more sensitive measure
in vitro for identifying MS patient status (288).
Other types of EVs have been explored as potential biomarkers in MS, including those
derived from platelets (289), leukocytes (304), and monocytes (304). Platelet activation can be
determined through the elevated expression of CD62P (P-selectin) and has been hypothesized to
be secondary to endothelial damage (289). Analysis of control and patient plasma revealed a twofold increase in CD41+ platelet-EVs in MS patients, providing a possible biomarker of disease
progression (289). Additionally, it has been demonstrated that CD45+ leukocyte-EV and CD14+
macrophage-EV counts differ significantly between healthy and MS patients (304). In regards to
other biofluids, analysis of human CSF has revealed the total number of EVs is higher in MS
patients compared to controls (293). Further subgrouping of EV populations in these samples
revealed the acute phase of the disease was associated with higher numbers of macrophage-EVs
than the stable or chronic phases and that these counts correlated linearly with gadoliniumenhancing MRI findings (293). These results were further supported using EAE animal models, as
the concentration of macrophage-EVs in CSF reflected the disease course and severity (293).
Currently, the identification of EV biomarkers in HD is still very early (305), whereas there
are currently no biomarkers yet available for ALS (306). Therefore, future research must expand
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into these additional neurodegenerative diseases. The potential to discovering a pan-EV biomarker
that could be used across all neurodegenerative conditions is unrealistic given our current
understandings of the diseases as well as the heterogeneity of each disease. In establishing
biomarkers, effort must be spent to create a standardized methodology for isolation and
quantitation of EVs from patient samples before they can be widely used as biomarkers in
neurodegenerative diseases. However, the ever-expanding field of EV biology holds promise in
one day using these tiny carriers of information as disease biomarkers.
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I. Abstract
Astrocytes are the most abundant glial cell type in the central nervous system (CNS) and are known
to fulfill critical homeostatic functions. Dysfunction of activated astrocytes is also known to
participate in the development of several neurological diseases. Astrocytes can be uniquely
identified by expression of the intermediate filament protein glial acidic fibrillary protein (GFAP).
Herein, we report on the development of a rigorous and sensitive methodology to identify GFAP+
exosomes in primary culture using flow cytometry. We then demonstrate that activated astrocytes
release increased amounts of exosomes in response to treatment with interleukin-1β. Using this
methodology, we report the identification of GFAP+ exosomes in blood and then use a mouse
model of inflammatory demyelination, experimental autoimmune encephalomyelitis (EAE), to
examine whether the abundance of GFAP+ exosomes in blood circulation changes during clinical
illness. We find a detectable increase in the presence of GFAP+ exosomes in EAE mice when
compared with non-EAE, control mice. Our data provide a novel perspective on the presence of
GFAP in blood as it identifies exosomes as potential astrocyte-derived signals within blood. These
data are complementary to previous clinical studies that reported elevated GFAP protein in blood
samples from multiple sclerosis (MS) patients during a clinical relapse. These data also reveal the
existence of a potential systemic role for astrocyte-derived exosomes in CNS conditions involving
inflammation such as multiple sclerosis.
Keywords: exosomes, astrocytes, multiple sclerosis, flow cytometry, GFAP
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II. Introduction
Exosomes are small, extracellular, membrane-bound vesicles (50-150 nm in diameter)
secreted by cells as a means of selective transfer of biologically active materials from one cell to
another that function as a mechanism of intercellular communication (256, 308-310). The impact
of exosomes on physiological functions is mediated, at least in part, by the molecular cargo (e.g.,
proteins and RNA) within the exosomes themselves. Recent findings demonstrating transport and
transfer of proteins and miRNA via exosomes has prompted increased attention on exosomes as
potential effectors in diseases as well as the potential to assay exosomes as novel biomarkers for
the diagnosis, prognosis and treatment of disease.
Exosomes develop from multivesicular bodies (MVBs), also known as endosomes. These
MVBs have a single outer limiting membrane (LM) that surrounds multiple luminal vesicles
(LVs). LVs are formed from the LM by inward budding. This process also enables the
incorporation of selected membrane proteins onto the surface of the MVBs (311). Intracellular
MVBs have one of two fates: they can either be fully degraded by the lysosomes, or they are
shuttled to the plasma membrane where they fuse and release LVs. It is the release of LVs into the
extracellular space when these vesicles are called ‘exosomes’ (209). Formation and shedding of
exosomes can be regulated by intracellular calcium levels (312, 313) or released constitutively, but
release can also be stimulated by inflammatory stimuli.
Within the central nervous system (CNS), exosomes are released by all cell types, including
neurons, microglia, oligodendrocytes, astrocytes, and neural stem cells (282, 314-316). The
contents of exosomes differ depending on cell of origin and pathological setting. For instance,
oligodendrocyte exosomes contain myelin proteins unique to oligodendrocytes (314) and
microglial exosomes contain proteins common to immune cells(316). Uptake of exosomes by
immune cells is a novel and potentially important mode of antigen transfer for MHC presentation
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that can promote T cell activation (311, 317, 318). These findings indicate that exosomes are
potential mediators of intercellular responses to inflammation and autoimmunity in CNS diseases
(310, 314, 319).
Exosomes are uniquely identified by several proteins, namely, the tetraspanin proteins CD63
and CD9, lipid raft-associated proteins, including flotillin-1, the heat shock protein HSPA8, and
the GTP binding protein EEF2, as well as internal, endosomal markers such as Alix and
Tsg101(230). While the contents of exosomes can also vary based on the cell of origin, exosomes
routinely contain proteins, peptides, mRNA, and/or miRNA(203). Exosomes released from one
cell can fuse to another 'target' cell through a non-classical active endocytotic process regulated by
the lipid raft protein, caveolin-1(320). Since exosomes are released from virtually all eukaryotic
cell types, their cell-of-origin can also be identified by retained cell-phenotype specific
markers(209), which makes exosomes potentially useful as sentinels for CNS function in
pathophysiology.
In this study we have focused on the emerging role of activated astrocytes as mediators and
dynamic participants in a growing number of neurological diseases(321-326). To investigate the
source and identity of exosomes, we have developed and validated a rigorous methodology to
identify astrocyte-derived exosomes in biological samples. We also demonstrate the utility of our
method by identifying astrocyte-derived exosomes in the circulating blood of mice and also report
elevated detection of these astrocyte-derived exosomes in the blood of mice in an animal model of
inflammatory demyelination. We hypothesize that these astrocyte-derived exosomes relay
systemic signaling related to disease and therefore represents a potentially important biomarker of
CNS function. The detection of astrocyte exosomes in blood also suggest that astrocytes may exert
a much broader impact on homeostatic and pathogenic regulation of signaling pathways on other
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cells during disease,
III. Materials and Methods
Animals and Experimental Autoimmune Encephalomyelitis. All procedures involving animals
were conducted with approval from the Institutional Animal Care and Use Committee at the
University of Connecticut School of Medicine and in accordance with guidelines set forth by the
National Research Council of the National Academies Guide for the Care and Use of Laboratory
Animals. Mice used in this study were included wildtype C57BL/6 (strain #000664) and GFAPCre mice (JAX strain #024098). To induce experimental autoimmune encephalomyelitis (EAE)
wild-type C57BL/6 mice (6-8 weeks old) were immunized with a 1:1 ratio of myelin
oligodendrocyte glycoprotein (MOG35-55, AnaSpec Inc.) dissolved in deionized water and
complete Freund’s adjuvant (CFA, Sigma) containing 0.5 mg of Mycobacterium tuberculosis
H37RA (Difco Laboratories: BD Diagnostics), as previously described(327). The MOG-CFA
emulsion was administered subcutaneously (s.c.) into the flanks of the hind-limbs (300 µg/mouse).
On days 0 and 2, pertussis toxin (PTX, List Biological) was injected intraperitoneally (i.p.) (500
ng/mouse). Weights and clinical scores were recorded daily. The following grading scheme was
used to score clinical signs of disease severity: 0, no clinical signs; 0.5, distal tail limpness; 1, full
tail atony; 2, hindlimb paresis; 3, unilateral hindlimb paralysis; 4, bilateral hindlimb paralysis; 5,
moribund. Blood was collected at peak clinical illness.
Primary Glial Cultures. Cultures were generated from cerebral cortices of neonatal C57BL/6
mouse pups (P0-P3) using a neural tissue dissociation kit (Miltenyi Biotec), as previously
described(328). Cells were plated into T75 flasks. The purity of each culture was confirmed and
consistent

with

previous

reports

of

90-97%

GFAP+

cells(328),

as

verified

by

immunocytochemistry (ICC) for GFAP for astrocytes (1:500, Sigma-Aldrich) and Iba-1 for
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microglia (1:1000, WAKO). Cells were grown to 70-80% confluence, washed two times with PBS
and incubated for 24 h in serum-free media (Dulbecco’s modified eagle medium, 1% Pen-strep,
Gibco) or in the presence of 10 ng/mL of IL-1β (Peprotech). Cell culture conditioned media (CCM)
was collected after 24 h, spun at 3000 x g for 15 minutes at room temperature, and stored at -80°C
until use.
Blood collection and Exosome Isolation. Blood was collected from CFA or EAE animals at preand peak clinical illness while under deep isoflurane anesthesia using a 1 ml syringe that had been
flushed with 0.5 M EDTA (Fisher Scientific). Exosome isolation workflow from blood samples is
shown in Fig 3A. Blood volumes collected ranged from 300-500 µl/animal. Blood was centrifuged
at 2000 x g for 15 min at room temperature and the upper plasma layer was drawn off. Plasma was
centrifuged at 1500 x g at room temperature and the supernatant drawn off. Plasma samples were
then subjected to a differential ultracentrifugation protocol for exosome isolation which were
confirmed by electron microscopy, western blotting and flow cytometry. Briefly, plasma was spun
at 12,000 x g for 30 min at 4°C. The supernatant was collected and run through a 0.22 µm spin
column (Millipore) at 12,000 x g for 4 min at room temperature. Filtrate was collected and equal
amounts were ultracentrifuged at 118,000 x g for 90 min at 4°C. The supernatant was removed
and the exosome pellets were re-suspended in 100 µl of sterile, 0.22 µm filtered PBS(-) and stored
at -80°C until use. All samples were validated by electron microscopy.
Exoquick-TCTM Precipitation. ExoQuickTM precipitation was carried out according the
manufacturer’s instructions (System Biosciences) and experimental workflow is depicted in Fig
1A. Briefly, 3 mL of conditioned media was mixed with 0.6 mL of ExoQuick-TCTM solution by
inverting the tubes several times. The samples were left to incubate overnight at 4°C then
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centrifuged twice at 1500 x g for 30 and 5 min, respectively, in order to remove the supernatant.
The supernatant was discarded and the pellet was re-suspended in 100 µL of 0.22 µm-filtered
PBS(-) and stored at -80°C until use.
Electron microscopy imaging. For negative staining, 15 µl drops of exosomes (in PBS) were
adsorbed onto activated copper grids with carbon coating (Electron Microscopy Sciences) for 15
min, washed by dabbing the grid onto three drops of deionized water, and stained with 1% uranyl
acetate (Electron Microscopy Sciences) for 1 min. Grids were imaged under a Hitachi H-7650
transmission electron microscope. For immunogold labeling, 15 µl of isolated exosomes were
adsorbed onto activated nickel grids with carbon coating for 15 min, Grids were then transferred
to 100 µl drops of PBS and washed twice for 3 min each. Following the PBS wash, grids were
transferred to 100 µl drops of a PBS/50 mM glycine solution and washed four times for 3 min
each. Grids were then blocked for 10 min on 100 µl drops of blocking buffer (1% BSA in PBS).
Grids were then incubated for 30 minutes at room temperature on 30 µl drops of primary antibody
against TSG101 (1:10 dilution in 1% BSA; Genetex) and GFAP (1:10 dilution in 1% BSA;
Millipore and Novus Biologicals). Grids were washed on 100 µl droplets of PBS three times for 5
min, blocked in 1% BSA for 5 min, and incubated with the appropriate secondary antibody
conjugated with 10 nm gold particles or 15 nm gold particles (Electron Microscopy Sciences; 1:15
dilution in blocking solution) for 30 minutes. Grids were washed three times for 5 min in PBS
followed by successive deionized water washes and counter-stained with 15 µl of 1% uranylacetate for 1 min. Excess uranyl-acetate was removed by gently blotting the grids and left to air
dry before imaging under a transmission electron microscope. Scanning electron micrographs were
performed on astrocyte in cultures that were fixed in 2.5% gluteraldehyde, post-fixed using
osmium tetroxide and then dehydrated using ethanol and processed by critical point drying. Cells
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were then spatter-coated with gold palladium and visualized using a JOEL Scanning EM (JOEL
USA Inc.).
Western blot analysis. Exosome preparations were lysed in RIPA buffer (with protease inhibitor
cocktail; Sigma) and separated by SDS-PAGE. Proteins were transferred to nitrocellulose and
immunoblotted using unconjugated antisera against CD63 (GeneTex), GFAP (Sigma) or TSG101
(GeneTex) that were then visualized by HRP-conjugated secondary antisera using
chemiluminescence (ECL; Amersham).
Flow cytometry. Flow cytometric analysis on exosome surface markers was performed at the
UConn Health flow cytometry core. CD63 (PE anti-mouse; 1:100; Biolegend), GFAP (Alexa Fluor
647 anti-mouse; 1:50; BD Biosciences), and TSG101 (FITC anti-mouse; 1:50; Lifespan
Biosciences) were added to sterile, 0.22 µm-filtered PBS (1x, pH 7.4) and spun at 10,000 x g at
4°C for 30 min to remove protein aggregates from the staining material. Supernatants were
transferred to fresh 0.2 mL PCR tubes and a 10 µl aliquot of exosome suspension was added. Tubes
were vortexed before being placed in a 37°C incubator for 60 min. Stained samples were then
transferred to round-bottom polystyrene tubes and analyzed using a Becton Dickinson (BD) FACS
Aria-II with a 130 µm nozzle and 10 PSI. Samples were run at the lowest flow rate to ensure the
most focused core stream until approximately 10,000 single events (based on a 1:1 ratio of side
scatter (SSC) pulse height to pulse area) were captured. Threshold was set based upon SSC at the
minimum value of 200 in order to remain unbiased for fluorescence particle detection. Noise was
determined by running the diluent (0.22 µm-filtered PBS) until ~500-1000 “noise events” were
captured. This was considered the background signal for the instrument. For analysis of exosomes,
a minimum of 10,000 events were captured and sorted for subsequent electron microscopy
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analysis. The detector voltage for Alexa Fluor 647 was set such that unlabeled EVs gave a signal
that was 2x the robust standard deviation of the "noise events" to clearly distinguish the sample
contents from the diluent and background signal from the instrument. This was determined by the
cytometer baseline report from BD Cytometer Setup and Tracking software. Reference beads of
known sizes (Spherotech, Nano Fluorescent Size Standard Kit; #NFPPS-52-4K) were also used to
determine instrument performance the day’s experiment as outline in section 3.1. Analysis and
gating was performed using BD FACS Diva software and FlowJo V10.2.
Statistical Analyses. Experiments were performed in quadruplicate technical replicates for each
of at least three biological replicates per condition. Comparisons between treatments were made
using Student’s t-test or repeated measures ANOVA with significance indicated where
appropriate. Data are presented as mean±SEM using scatter plots to demonstrate data distribution
within each treatment group. The null hypothesis for all experiments was P<0.05.
IV. Results
3.1 Identification of astrocyte exosomes in primary cultures.
To establish the identity of exosomes from astrocytes in more complex biological fluids, we
first collected serum-free media from primary astrocytes in culture in order to benchmark the
approach and reagents under these defined conditions. Exosomes were collected and then analyzed
by transmission electron microscopy, which revealed negatively stained exosome-like double
membrane vesicles with size ranges between 50-150 nm, with a stereotypical cup-shaped
morphology (Fig 1B). The identity of these extracellular vesicles as exosomes was then confirmed
by immunogold labeling with the exosome marker TSG101, in conjunction with the astrocyte
marker, glial fibrillary acidic protein (GFAP) (Fig 1C). Together, these histomorphological

70

features confirmed the collection of exosomes from the astrocyte-conditioned media.
We next sought to determine whether flow cytometry could also be adopted as a means to
reliably identify exosomes in media samples conditioned by primary astrocytes in culture. Flow
cytometry analysis of exosomes is presently considered a highly desirable, widely accessible
technology by which to assess the presence of small vesicles, however, the standardization of this
method for small particle analysis is still in development with no final consensus on the exact
method to use. A significant limitation of this analysis remains the resolution of size using forward
angle light scatter (FALS) to trigger a particle “event” on the flow cytometer. Due to their small
size, extracellular vesicles cannot be distinguished using a traditional forward scatter signal
detector or photodiode. Some customized and specialized instrumentation uses a more sensitive
photomultiplier tube for FALS (Stoner et al. 2016), however not all labs have access to such
instrumentation. On the other hand, side angle light scatter (SSC) and fluorescence are both
detected using the more sensitive photomultiplier tube (PMT) which allows for resolution of low
signals such as those produced by small vesicles with respect to the background electronic “noise”
of the instrument. Taking advantage of these detectors, we set the cytometer to trigger events based
on the lowest possible setting for SSC and subsequently examined the fluorescence of any particle
that registered above the noise of the instrument for the given fluorescence detector. Noise was
determined by acquiring a sample of the media used to dilute the vesicles (FIG 1D). The
instrument performance for this detection method was determined using a set of yellow-fluorescent
nano-calibration beads on each experimental day to ensure detection of a 200 nm particle (Fig 1E).
Although polystyrene bead particles do not have the same refractive index as lipid vesicles for the
generation of SSC, this test ensured the instrument was at least capable of detecting small particles
above noise. Another caveat to the use of flow cytometry for small particle detection is the
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possibility of larger aggregates of particles ("swarm detection"), where several vesicles were
detected simultaneously (220). To reduce this possibility, all exosome samples were run both
undiluted and diluted to ensure the fluorescence intensity of the signal remained constant. In
addition to the dilution of the sample, each exosome sample was run simultaneously with an
unstained sample, a sample allowed to react with an isotype control Ab, and a sample which only
contained antibody with dilution media. This strategy then enabled us to discern the labeled
exosome signal from aberrant signal from unbound antisera and also non-specific binding of Ab
to exosomes (Fig 1F). Using this step-wise approach we identified exosomes bound to Abs specific
for the astrocyte marker GFAP as well as canonical exosome markers TSG101 and the tetraspanin
protein, CD63 (Fig 1F).
3.2 Increased astrocyte exosome release in response to IL-1β.
We next tested whether our methodology could be used to identify changes in exosome
release. Previous work has shown that IL-1β is a potent inducer of exosome release. We began by
examining astrocytes using scanning electron microscopy to determine if membrane
perturbations/projections, associated with extracellular vesicle release in other cell types could be
observed in astrocytes. In untreated astrocytes (Fig 2A), the plasma membrane was observed to
have many long, sinewy projections. In contrast, shortly after treatment with IL-1β, the cell surface
of astrocytes was noticeably different with numerous bulbous protrusions which resemble
microblebs (Fig 2B), which reflect intracellular budding events consistent with the process of
exosome release from exocytosis of MVBs (Gyorgy et al. 2011). This subcellular structural
response was then associated with a measurable increase in the abundance of exosomes into the
cell culture media (Fig 2C-G). To test if our flow cytometry approach could be used to identify
exosomes release from astrocytes activated by IL-1β we assayed the proportion of exosomes
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released into the conditioned media collected 24 hours after treatment. IL-1β treatment
significantly increased the abundance of CD63+ particles smaller than 220 nm (exosomes) (Fig
2C, P<0.001). The proportion of exosomes released by astrocytes was also increased (Fig 2D,
P<0.01), and we confirmed the exosomal origin of these extracellular vesicles using a second
marker Tsg101, which also identified a significant increase in response to IL-1β treatment (Fig
2E, P<0.05). We further validated the identity of increased exosomes as having been derived from
astrocytes by determining the relative increase in the proportion of GFAP+/CD63+ (Fig 2F,
P<0.01) and GFAP+/TSG101+ exosomes (Fig 2G, P<0.05). Thus, we confirmed the utility of all
three markers of astrocyte-derived exosomes (GFAP, CD63 and TSG101) and determined that
these markers exhibited remarkable concordance between each marker in terms of its magnitude
of increase in response to IL-1β treatment. Once again, for each exosome isolate tested, we verified
by TEM the appropriate size class of extracellular vesicles collected from each sample (data not
shown).
3.3 Identification of astrocyte exosomes in peripheral blood samples.
The objective of developing a validated approach to identify exosomes from primary
astrocytes conditioned media was to be able to apply this approach to more complex biological
fluids. Interestingly, the astrocyte marker protein GFAP has been reported to be found in blood
from patients suffering from a number of neurodegenerative diseases including Alzheimer’s, ALS,
and multiple sclerosis (329, 330). Therefore, we hypothesized that GFAP identified in blood
samples may indicate the presence of astrocyte-derived exosomes. This would suggest that
astrocyte-derived exosomes are present in peripheral circulation.
To test this possibility, we collected blood samples from naïve C57BL/6 mice and isolated
exosomes from blood plasma using a differential centrifugation protocol (331). Exosomes isolated
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by this method (Fig 3A) were analyzed by TEM to determine if the vesicles present had all the
characteristics of exosomes we observed in our conditioned media samples. Negative staining
confirmed a distinctive cup-shaped morphology of the double membrane vesicles and size class
consistent with exosomes, ranging from 50-150 nm size range, in these blood plasma samples (Fig.
3B). Immunogold labeling of exosomes with the astrocyte marker GFAP identified astrocytederived exosomes in these samples from peripheral blood (Fig. 3C).
To address whether these GFAP-positive exosomes in blood were indeed derived from
astrocytes in the CNS and not from other peripheral tissues that have been suggested to be
immunoreactive for GFAP(330), we collected blood samples from CRE recombinase mice in
where the transgene was under the control of the mouse GFAP promoter (B6.Cg-Tg(Gfapcre)73.12Mvs/J)(332). CRE mRNA expression in these mice is limited to the brain and spinal cord
whereas no CRE expression is detected in peripheral tissues (data not shown). Blood plasma
samples were collected and the exosome pellet subjected to western blot analysis for the exosome
marker CD63, as well as astrocyte specific markers GFAP and the transgene product, CRE protein.
This western blot analysis confirmed both expression of exosome marker, CD63 (Fig. 3D), as well
as the astrocyte markers GFAP (Fig. 3D) and the gene product of the transgene, CRE (Fig. 3E).
Together, these findings confirmed that GFAP+ exosomes present in peripheral blood circulation
of naÏve adult mice were of astrocytic origin.
3.4 Elevated astrocyte-derived exosomes in blood from clinically affected EAE mice.
We next examined whether the amount of astrocyte exosomes in peripheral blood changed
during course of clinical disease in a model of a neurological disease. To test this, we used the
same strain of C57BL/6 mice for which we derived our primary glial cultures, and immunized
adult mice to induce EAE using myelin oligodendrocyte glycoprotein (MOG) peptide as described
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above. This model of inflammatory demyelination induces a robust, reproducible, and predictable
CNS demyelination that is used to model the immune-mediated pathology of multiple sclerosis.
In this set of experiments, mice immunized with MOG35-55 peptide, or given an equal volume of
CFA, were monitored daily for signs of clinical illness and at the peak clinical disability (Fig 3F),
Blood was collected from mice either one week following immunization with MOG, or at the peak
of clinical disability (Day 16 post immunization (Fig 3F). Blood samples from CFA-treatment
groups were time-matched to either 7 or 16 day time points (Fig 3G,H) Exosome samples were
then analyzed using flow cytometry to determine the abundance of GFAP+ exosomes in the EAE
group when compared to CFA controls. Flow cytometry identified increased a low abundance of
GFAP+ exosomes in all samples and the relative abundance in CFA-treated animals did not differ
from MOG-immunized animals 7 days post injection (Fig 3G; n=4-6/group). In contrast, analysis
of GFAP+ exosomes from blood of EAE mice taken during peak clinical disability (Day 16)
revealed a significant increase in the relative abundance of GFAP+_exosomes in EAE mice when
compared with time-matched CFA-only treated controls (Fig. 3H). Taken together, these data
indicate that neuroinflammation associated with EAE was associated with increased presence of
astrocyte-derived exosomes in the blood.
V. Discussion
Accumulating evidence indicates that astrocyte dysfunction contributes to the pathogenesis
of several prevalent neurodegenerative diseases(333-336), including Alzheimer's disease(337),
amyotrophic lateral sclerosis (ALS)(338), Parkinson's disease(339, 340), Huntington's
disease(341-343), Alexander's disease(333), and multiple sclerosis(335, 344, 345). Alterations in
astrocyte function are also reflected in their exosome function. For instance, motor neuron death
in ALS is non-cell autonomous and results from toxic secreted factors from astrocytes(346-349).
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Exosomes collected from SOD1 mutant astrocytes have been found to contain the mutant SOD1
protein, that is transferred into cultured motor neurons when the exosomes fuse(282). Exosomemediated transfer of apoptotic proteins also provides a potential mechanism for glial cell death
Alzheimer's disease(319). The contents of astrocyte exosomes are unknown, but given the
important physiological roles for astrocytes in neural development(350-352), myelination(344,
353), synaptic transmission(354, 355), neurovascular coupling(356, 357), regulation of CNS
infections(358-361) and inflammation(327, 362-364). The context of astrocyte activation in
disease has lead to proposed phenotype classification with "A1" pro-inflammatory and "A2" antiinflammatory states(135, 137, 365-368). Our in vitro experiments using primary astrocytes in
culture indicate that the abundance of exosomes can be increased in response to IL-1β, which is
may be indicative of an "A1" state, whereas our in vivo findings may reflect activation but perhaps
a mix of A1 and A2 states. Nevertheless, our approach to study exosomes from astrocytes may be
applied to qualify the exosomal components related to these different activation states. Our
findings demonstrate that astrocytes respond to pro-inflammatory conditions by increasing the
release of exosomes. Our new validated protocol for detecting astrocyte-derived exosomes in
conditioned media has also enabled us to assay astrocyte-derived exosomes in more complex
biological samples (i.e. blood plasma).
In this study, we focused on the potential utility of identifying astrocyte exosomes as they
may relate to study of their function in primary culture and analysis of these extracellular vesicles
in blood, by applying our methods to an animal model of multiple sclerosis (MS). As mentioned,
MS is a progressive, demyelinating neurodegenerative disease characterized by development of
autoreactive T cells, CNS demyelination, and chronic astrogliosis. A number of studies suggest
that reactive astrocytes contribute heavily to the disease process of demyelination(143, 369, 370).
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The interplay between the central nervous system and the immune system in the development and
progression of MS, and in particular the potential role of astrocytes as regulators of T cell activities
in the CNS raises intriguing questions about the many ways in which astrocyte dysfunction may
contribute to pathology in this disease(134, 371). Importantly, how these systems counter-regulate
during the course of disease is a matter currently under investigation.
Our findings are the first to identify a potentially new and precise process through which
the CNS and immune systems may interact: the release of activated, A1-type astrocyte (GFAP+)
exosomes into the blood may indicate a previously unrecognized, wide-ranging influence of CNS
astrocytes on systemic physiology in disease. Our findings also identified GFAP positive
exosomes in the peripheral circulation of mice and increased levels of circulating exosomes in the
mouse model of multiple sclerosis, EAE. This suggests that astrocytes may exert a much broader
impact on homeostatic and pathogenic regulation of signaling pathways on other cells during
disease. While we have not determined whether these changes reflect an alteration in the
physiological function of exosomes released constitutively versus in response to inflammation, we
would hypothesize, based on the known function of astrocytes in disease models, that the content
and function of exosomes would mirror the (patho)physiology of the CNS. For this reason we
would propose that a potential development from these findings would be the identification of
specific content markers from within these exosomes that could be used as a biomarker to monitor
the state of the CNS in health or disease.
Experimental evidence for a contributing role of exosomes to the progression of multiple
sclerosis is currently limited, yet studies identifying the presence of extracellular vesicles in
numerous body fluids including cerebrospinal fluid (285), blood (287), and urine (372). The
findings suggest that monitoring of CNS-derived extracellular vesicles, including exosomes, may
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offer utility for monitoring disease progression and/or responsiveness of MS patients to therapies.
For instance, Minager et al. observed an increase in endothelial derived microparticles in the
plasma of MS patients during a relapse that showed a subsequent reduction to control levels during
remission (287). Exosomes have also been investigated for use as a potential therapeutic to
stimulate remyelination in MS patients as evidenced by the identification of micro-RNA (miRNA)
species within the cargo of exosomes that can improve remyelination. This evidence is based off
the finding that exosomes isolated from interferon-γ stimulated rat bone marrow derived dendritic
cells containing miRNA-219, which is capable of increasing baseline myelination, reducing
oxidative stress, and improving remyelination in rats following a lysolecithin demyelinating injury
(373). These exosomes could also be administered intranasally to rats to improve myelination.
Beyond a potential therapeutic use of exosomes in MS, there is evidence for their use as diagnostic
markers in patients receiving treatments. miRNA species have been detected in the blood and urine
of MS patients undergoing natalizumab therapy (372).
The aforementioned findings provide additional future avenues of investigation for the
potential of astrocyte-derived exosomes in peripheral blood circulation in a wide variety of
neurological conditions in which changes in astrocytes have been implicated. Currently, exosomes
are often viewed as passive players: a reflection of the development and progression of numerous
neurodegenerative diseases. Yet, recent studies provide compelling evidence for an active,
participatory

role

for

exosomes,

including

astrocyte-derived

exosomes,

in

chronic

neurodegenerative diseases. Astrocyte-derived exosomes have already been implicated in
contributing to the progression and pathogenesis of amytrophic lateral sclerosis (ALS)(120, 336),
Alzheimer’s(336), and Parkinson’s(336). In each of these neurodegenerative diseases, astrocyte
exosomes were shown to carry the mutant version of superoxide dismutase-1 enzyme(282),
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amyloid precursor protein(374), and alpha-synuclein(300), respectively. However, there has been
no definitive evidence for a role of astrocyte exosomes in contributing to the pathogenesis of
multiple sclerosis. This is perhaps due to evidence for an active and dual-role of astrocytes in MS
pathogenesis. It is known that astrocytes play diverse roles in CNS development and disease, but
in MS, specifically, astrocytes garner attention for their potential to enhance immune responses
through expression of major histocompatibility complex (MHC) class I and class II molecules(375,
376) and activation of CD8+ and CD4+ T cells(377-379). Conversely, astrocytes may also elicit
neuroprotective functions: release of anti-inflammatory molecules (i.e., TGF-β), supporting
oligodendrocyte regeneration, and facilitating repair of the blood-brain-barrier (120).
Understanding the precise function of astrocytes may be revealed by the exosomes they shed in
response to CNS injury. Future experiments should consider the cargo of astrocyte exosomes and
their potential functional impact. One of our hypotheses is that the effect of astrocyte exosomes is
a function of time. It could be that early on in the disease process astrocyte exosomes have a
negative role in modulating the immune response, which results in the demyelinated lesions and
relapses commonly observed with MS. As the immune response lessens and patients enter
remission, astrocyte exosomes could have a positive role in modulating the recovery of the lesions
vis-à-vis remyelination. Future studies will be required to better understand this interesting dualrole of astrocyte exosomes in the disease process.
Presently, the cause of multiple sclerosis is not known. Our finding of elevated numbers of
astrocyte-exosomes in peripheral circulation during homeostasis and during disease creates a
potentially interesting avenue of study into better understanding the disease process. These
findings provide a new perspective by which we may better understand this disease and potentially
develop new approaches to monitor the course of and understand the pathophysiology of diseases
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like multiple sclerosis.
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VI. Figures
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Figure 3-1: Identification and characterization of a flow cytometry methodology to identify
astrocytic exosomes in media from primary astrocyte cultures. (A) Work-flow scheme of
exosome isolation from primary culture conditioned media. (B) Negative stain electron
micrographs of exosomes isolated from media using a commercially available kit which allows
for rapid isolation and purification of exosomes (C) Electron micrographs of astrocyte-derived
exosomes in media verified using immunogold electron microscopy against the exosome marker
TSG101 (15 nm gold-particle) and astrocyte marker GFAP (10 nm gold particle). (D) The diluent,
phosphate-buffered saline, was analyzed by the flow cytometer prior to any exosome analysis to
determine the background noise of the machine prior to each exosome sample. (E) Yellowfluorescent calibration beads of different known nanometer (nm) sizes were used to identify both
the threshold for detection of the flow cytometer prior to the analysis of exosome samples and the
relative location of that particle size class. (F) Exosome were stained with anti CD63, anti-GFAP
and anti-TSG101 (right panels) or corresponding isotype controls (left panels). Serial dilutions for
each antisera were performed and compared to the isotype-matched control for each, to determine
the optimal dilution that would provide the best signal-to-noise ratio for flow cytometric analysis.
Scale bars in B,C = 100nm.
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Figure 3-2: Quantitative increase in detection of astrocytic exosomes in media from primary
astrocyte cultures following treatment with IL-1β. Scanning electron micrographs of astrocytes
under control conditions (A) and 1 hour after IL-1B-stimulation (B). Magnifications in A&B are:
6500x,left panel, and 10000x, right panel). Note (arrows) the membrane perturbations resulting
from cytokine stimulation that have been associated with the process of extracellular vesicle
release (in B). (C-G) Analysis of astrocyte-derived exosomes from primary glial cultures using
flow cytometry using antibodies against CD63 (C), GFAP (D),and Tsg101 (E) show elevated
detection of events (exosomes) following IL-1β treatment. Additional analyses of GFAP+/CD63+
(F) and GFAP+/Tsg101+ (G) labeling confirmed an increased relative abundance of astrocytederived (GFAP+) exosomes (CD63+ or Tsg101+). Control (vehicle) treated cultures ("Naive") had
an identifiable amount of exosomes in conditioned media but the proportion of exosomes detected
was markedly increased in response to IL-1β treatment. Significance is indicated where: *,P<0.05;
**,P<0.01, ***,P<0.001 t-test. Scale bars in A,B = 1 µm
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Figure 3-3: Identification and characterization of astrocyte-derived exosomes in blood
plasma from mice and increased detection of GFAP+ exosomes in blood from mice during
EAE. (A) Work flow scheme for exosome isolation from blood plasma. (B) Electron micrographs
of extracellular vesicles isolated from peripheral blood plasma revealed prototypic "cup-shaped
morphology" of the appropriate size class for exosomes. (C) Immunogold electron microscopy
using anti-GFAP and gold particle conjugated secondary antisera (15 nm) identified exosomes
from blood plasma that were astrocyte-derived. Scale bars: size bar, A = 100 nm; B =100 nm. (D)
Western blotting analysis of the EM exosome preparations from blood plasma analyzed in A, B
confirmed detection of exosomal (CD63) and astrocytic markers (GFAP) in the exosome pellet.
(E) Validation of astrocytic origins using expression of CRE recombinase protein in blood plasma
as measured by western blotting from exosome preparation from GFAP-CRE transgenic mice.
Samples were diluted (as indicated) to demonstrate that antibody reactivity was serially diminished
which supports the specificity of the antibody binding. E' represents a shorter exposure of the blot,
while E'' represents a longer exposure time which were needed to visualize CRE-reactive bands in
the more diluted samples, respectively. The CRE-reactive bands were of the same molecular
weight as observed in the most concentrated sample. (F) Clinical EAE scores of myelin
oligodendrocyte glycoprotein (MOG) immunized C57BL/6 mice (n=6) and control (CFA
inoculated; n=4). Mice were euthanized one week following immunization or time point of peak
clinical illness (day 16). Euthanization of CFA control animals were time-matched for either day
7 (arrow) or day 16 (arrow), respectively, for blood collection and blood plasma exosome isolation.
(G) Flow cytometry analysis of blood plasma exosomes from EAE and control (CFA) mice at a
pre-clinical disease timepoint (day 7), and (H) at the time of peak clinical illness (Day 16). GFAP+
exosomes in blood of control mice did not differ in preclinical disease (Day 7) MOG immunized
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mice, whereas a notable increase in the detection of astrocyte-derived exosomes in blood plasma
was observed in mice at the time of peak clinical illness in EAE. Significance is indicated where:
(F) ****, P<0.0001, 2-way ANOVA; (H) **, P=0.0031; t-test.
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I. Abstract
Extracellular vesicles (EVs) are emerging as potent mediators of intercellular communication with
roles in inflammation and disease. In this study, we examined the role of extracellular vesicles
from blood plasma (pEV) in an experimental autoimmune encephalomyelitis mouse model of
central nervous system demyelination. We determined that pEVs induced a spontaneous relapsingremitting disease phenotype in MOG35-55-immunized C57BL/6 (R/R-EAE) mice. This modified
disease phenotype was found to be driven by CD8+ T cells and required fibrinogen in pEVs.
Analysis of pEVs from relapsing-remitting multiple sclerosis (RRMS) patients also identified
fibrinogen that was uniquely citrullinated. Together, these data suggest that fibrinogen in pEVs
contributes to the perpetuation of neuroinflammation and relapses in disease.

Significance Statement
In this novel report, we show that fibrinogen, identified by proteomics to be present in blood
plasma extracellular vesicles (EVs), is sufficient and required for autoimmune-mediated relapsing
disease in a murine model of multiple sclerosis (MS). Unique to this model is that plasma EVs
induced CD8-mediated disease and hence models human MS, which is not typically the case for
experimental murine models. Strikingly, an analysis of human plasma EVs identified unique
citrullination motifs of fibrinogen in MS patient samples thereby providing a compelling
association between our experimental findings and autoimmunity in human MS. Our new system
unveils a major biomedical breakthrough by linking EVs with relapsing disease using cutting edge
proteomics, and solid preclinical human data.
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II. Introduction
Successful translation of discovery research into clinical efficacy is often hampered by the
authenticity of experimental animal models to faithfully recapitulate disease pathogenesis. For
instance, study of the adaptive immune responses in experimental autoimmune encephalomyelitis
(EAE) mouse models of multiple sclerosis (MS) have become a basis for our understanding and
pre-clinical therapeutic development (96). Yet, the immunological phenotype of MS patients
notably differs from mice in which immunization with myelin peptides induce robust T-cell
responses (380). Significant attention on CD4+ T cells in MS has been supported by both GWAS
identified risk susceptibility genes for MS and the central role of CD4+ T cells in many EAE
mouse models (99, 381, 382). However, CD4+ T cells do not underlie the clinical disease course
in human MS patients and interrogation of infiltrating lymphocyte subtypes in MS patients has
revealed a predominance of CD8+ T cells over CD4+ T cells (117, 383, 384). The repertoire of
CD8+ T cells in the CSF of MS patients, and to a lesser extent in blood, reflects elevated levels of
CD8+ T cells also identified in lesions within the CNS (385). These findings have led to important
questions on the etiology of CD8+ T cell responses, their potential roles in mediating clinical
exacerbations, and how to model this immune response in mice (386). The enrichment of CD8+ T
cells in MS suggests a critical effector role for CD8+ T cells in this disease, but the inherent
difficulty in modeling spontaneous CD8+ T cells in EAE models has hindered rigorous study of
encephalitogenic CD8+ T cells in the context of autoimmunity and MS.
Extracellular vesicles (EVs) have emerged as a potent mediators of immunity (387) with
the potential for affecting CD8+ T cell activity. EVs are nano-sized membrane particles released
by cells that represent an evolutionarily conserved mode of intercellular communication (388).
Interest in EVs has been stimulated by their emerging roles in disease and potential use as
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prognostic biomarkers (205). Interest in EVs is driven by recent experimental evidence
demonstrating EV-directed intercellular communication contributes to cancer, inflammatory,
neurological and autoimmune diseases (389). Hence, EVs represent a rapidly evolving field with
potential to understand complex diseases. In particular, the innate cellular complexity and relative
inaccessibility of the CNS offer the potential for EV biology to provide better understanding and
insight to monitor inflammatory and degenerative changes (261). Plasma EVs (pEVs) have also
been reported to reflect features of inflammation in human neurological diseases such as
Alzheimer’s disease(390), Parkinson’s disease (300), and MS (284). Yet, how pEVs may
contribute to the autoimmunity of multiple sclerosis has not been elucidated.
In this study, we assessed the functional impact of pEVs on neuroinflammation and clinical
disability in a mouse model of CNS demyelination. We report that pEVs from naive C57BL/6
mice when transferred into mice with active EAE results in a distinct spontaneous relapsingremitting EAE phenotype characterized by a prominent contribution of CD8+ T cells. Proteomic
analysis identified a causal role for fibrinogen in pEVs inducing the unique clinical and
immunological phenotype in this pEV-EAE model. We characterize the pEV-EAE approach as
representing an authentic immunological system with utility for disease modeling and
understanding the etiology of CD8+ T cell responses in disease relapses in MS which may have
implications for translation of experimental findings to human patients.
III. Materials and Methods
Animals. Mice used in this study included wild-type male C57BL/6 (strain #000664, The
Jackson Laboratory)) and Fib-/-mice(391) (kindly provided by Jay Degen).

All procedures

involving animals were conducted with prior approval from the Institutional Animal Care and Use
Committees at the University of Connecticut School of Medicine and the University of California,
San Francisco in accordance with guidelines set forth by the National Research Council of the
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National Academies Guide for the Care and Use of Laboratory Animals. Mice were housed under
a 12:12 light/dark cycle, 55 ± 5% relative humidity, and a temperature of 20 ± 2°C with access to
standard laboratory chow and water ad libitum. They were housed in social groups of a maximum
of 5 mice each in standard mouse housing cages and bedding.
Experimental Autoimmune Encephalomyelitis (EAE). was induced in wild-type
C57BL/6 mice (8-12 weeks old) by immunizing with a 1:1 ratio of myelin oligodendrocyte
glycoprotein (MOG35-55, AnaSpec Inc.) dissolved in deionized water and complete Freund’s
adjuvant (CFA, Sigma) containing 0.5 mg of Mycobacterium tuberculosis H37RA (Difco
Laboratories: BD Diagnostics), as described in previous studies (162, 307). The MOG-CFA
emulsion was administered subcutaneously (s.c.) into the flanks of the hind-limbs (300 µg/mouse).
On days 0 and 2, pertussis toxin (PTX, List Biological) was injected intraperitoneally (i.p.) (500
ng/mouse). Weights and clinical scores were recorded daily by an experimenter blinded to
experimental treatment of subjects. Clinical signs of disease severity were: 0, no clinical signs;
0.5, distal tail limpness; 1, full tail atony; 2, hind-limb paresis; 3, unilateral hind-limb paralysis; 4,
bilateral hind-limb paralysis; 5, moribund.
Blood collection and pEV Isolation. Whole blood from naïve C57BL/6 mice was
collected while under deep isoflurane anesthesia using a 1 ml syringe that had been flushed with
0.5 M EDTA (Fisher Scientific). Whole blood was collected from confirmed Fib-/-and
Fib+/+littermates, and were coded for genotype and blinded prior to pEVs isolation and EAE
experiments. Injected isolated pEVs into any single recipient were equal to the blood volume of
one mouse (1.46 mL) whole blood. Whole blood was centrifuged at 2000 x g for 15 min at room
temperature and the upper plasma layer was drawn off. Plasma was centrifuged at 1500 x g at
room temperature and the supernatant drawn off. Plasma samples were then subjected to a
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differential ultracentrifugation protocol for extracellular vesicle isolation as previously described
(307). Briefly, plasma was spun at 12,000 x g for 30 min at 4°C. The supernatant was collected
and equal amounts were subjected to ultracentrifugation at 150,000 x g for 90 min at 4°C. The
supernatant was removed and the extracellular vesicle pellets were re-suspended in 150-200 µl of
sterile, 0.22 µm filtered PBS and stored at -80°C until use. All samples were validated by electron
microscopy.
CD8 and Isotype antibody injections. 500 µg of either αCD8 (InVivoMAb anti-mouse
CD8 [Lyt 2.1, Clone: 116-13.1 (HB-129)], Bio X Cell, West Lebanon, New Hampshire) or αCD8isotype antibody (InVivoMAb mouse IgG2a Isotype control [Clone: C1.18.4], Bio X Cell, West
Lebanon, New Hampshire) in sterile PBS was injected intraperitoneally into pEV-injected MOGEAE mice at peak clinical EAE and 5 days later.
Cytometry by time of flight. Brains were obtained from vehicle or pEV-injected MOGEAE mice 10 days following injections. Brains were digested with a collagenase/DNase solution
and lymphocytes isolated using a 70%/40% percoll gradient. Each sample (n = 4) was labeled with
Cell-ID cisplatin to identify live and dead cells and subsequently barcoded with Cell-ID Pd
barcoding kit [all mass cytometry (CyTOF) reagents are from Fluidigm, San Francisco, CA]. The
four samples were permeabilized with methanol and incubated with Fc receptor blocking solution
and a 31 heavy-metal conjugated antibody panel, including seven signaling markers, as previously
described20. DNA was labeled using Cell-ID Intercalator-Ir. The samples were spiked with
normalization beads and analyzed by a mass cytometer (HELIOS, Fluidigm) at Jackson
Laboratories (Farmington, CT). The data were debarcoded using the Fluidigm Debarcoder v1.04.
A single-cell and live-cell gate were identified in each sample. The samples were downsampled to
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ensure equal numbers of cells per sample for ViSNE analysis (FlowJo, FlowJo, LLC, Ashland,
Oregon) (392).
Electron microscopy imaging. For negative staining, 20 µl drops of pEVs (in PBS) were
adsorbed onto activated copper grids with carbon coating (Electron Microscopy Sciences) for 15
min, washed by dabbing the grid onto three drops of deionized water, and stained with 1% uranyl
acetate (Electron Microscopy Sciences) for 1 min. Grids were imaged under a Hitachi H-7650
transmission electron microscope. For immunogold labeling, 20 µl of isolated pEVs were adsorbed
onto activated nickel grids with carbon coating for 15 min. Grids were then blocked for 10 min on
100 µl drops of blocking buffer (1% NGS in PBS). Grids were then incubated for 60 minutes at
room temperature on 25 µl drops of primary antibody against fibrinogen (1:10 dilution in 1% NGS;
Dako; catalog ID: A0080) and flotillin-1 (1:10 dilution in 1% NGS; BD Transduction; Clone
18/Flotillin-1). Grids were washed on 100 µl droplets of PBS three times for 5 min, blocked in 1%
NGS for 5 min, and incubated with the appropriate secondary antibody conjugated with 15 nm
gold particles or 10 nm gold particles (Electron Microscopy Sciences; 1:15 dilution in blocking
solution) for 60 minutes, respectively. Grids were washed three times for 5 min in PBS followed
by successive deionized water washes and counter-stained with 25 µl of 1% uranyl-acetate for 1
min. Excess uranyl-acetate was removed by gently blotting the grids which were then left to air
dry before imaging under a transmission electron microscope.
Human Blood Samples. Plasma samples were obtained from a total of three patients with
MS and three healthy, non-diseased controls, after patient consent (Supplementary Table 5). This
study was approved by the Office for the Protection of Research Subjects at University of Illinois
at Chicago and the Department of Defense Human Research Protection Office. All patients with
MS were diagnosed with RRMS and one with secondary progressive MS according to the revised
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McDonald criteria. At the time of blood collection, all patients with RRMS were in remission. All
but one patient with MS were under specific MS medication. Three milliliters of blood was
collected in tubes with 0.5M ethylenediaminetetraacetic acid (EDTA; BD, Franklin Lakes, NJ).
Blood was pre-spun at 1500 x g for 15 mins at room temperature to isolate plasma. Plasma was
then spun at 12,000 x g for 30 minutes to remove contaminating microvesicles and flash-frozen on
dry ice until extracellular vesicle isolation.
Western blot analysis. pEV preparations from either mouse or healthy human subjects or
RRMS patient plasma were lysed in RIPA buffer (with protease inhibitor cocktail; Sigma) and
separated on a pre-cast 12% Gel (Bio-Rad) by SDS-PAGE. Proteins were transferred to
nitrocellulose and immunoblotted using unconjugated antisera against fibrinogen (Dako; catalog
ID: A0080; 1:2500), fibrinogen alpha chain (Abnova; catalog ID: H00002243-D01P; 1:1000), and
the EV marker flotillin-1 (BD Transduction; Clone 18/Flotillin-1; 1:500) that were then visualized
by

HRP-conjugated

secondary

antisera

(Vector

Laboratories;

1:1000-5000)

using

chemiluminescence (Clarity Western ECL; Bio-Rad). Images were captured using a ChemiDoc
XRS+ imaging system (Bio-Rad). Human plasma plasminogen-depleted fibrinogen (EMD
Millipore #341578) or mouse plasma plasminogen-depleted plasma fibrinogen (abcam #ab92791)
(100 ng) were used as positive controls for the identification of fibrinogen chains on pEVs.
In solution Protein Digestion. Extracellular vesicle pellets were resuspended in 1XRIPA
buffer containing Halt Protease Inhibitor Cocktail (ThermoScientific Prod# 87786). Samples were
homogenized by sonication, and cleared by centrifugation at 14,000 rpm, 4°C, 10 min on a desktop
centrifuge. Proteins were extracted by Chloroform/Methanol precipitation using established
protocols. Protein pellets were dissolved and denatured in 8M urea, 0.4M ammonium bicarbonate,
pH 8. The proteins were reduced by the addition of 1/10 volume of 45mM dithiothreitol (Pierce
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Thermo Scientific #20290) and incubation at 37ºC for 20 minutes, then alkylated with the addition
of 1/10 volume of 100mM iodoacetamide (Sigma-Aldrich #I1149) with incubation in the dark at
room temperature for 20 minutes. The urea concentration was adjusted to 2M by the addition of
water prior to enzymatic digestion at 37°C with LysC (Wako, #125-05061) for 4 hours, then
trypsin (Promega Seq. Grade Mod. Trypsin, # V5113) for an additional 16 hours. Protease:protein
ratios were estimated at 1:50. Samples were acidified by the addition of 20% trifluoroacetic acid,
then desalted using C18 MacroSpin columns (The Nest Group, #SMM SS18V) following the
manufacturer’s directions with peptides eluted with 0.1% TFA, 80% acetonitrile. Eluted sample
was speedvaced dry and dissolved in MS loading buffer (2% aceotonitrile, 0.2% trifluoroacetic
acid). A nanodrop measurement (Thermo Scientific Nanodrop 2000 UV-Vis Spectrophotometer)
determined protein concentrations (A260/A280). Each sample was then further diluted with MS
loading buffer to 0.08µg/µl, with 0.4ug (5µl) injected for LC-MS/MS analysis.
LC-MS/MS on the Thermo Scientific Q Exactive Plus. LC-MS/MS analysis was
performed on a Thermo Scientific Q Exactive Plus with a Waters nanoAcquity UPLC system,
using a Waters Symmetry® C18 180µm x 20mm trap column and a ACQUITY UPLC PST (BEH)
C18 nanoACQUITY Column 1.7 µm, 75 µm x 250 mm (37ºC) for peptide separation. Trapping
was done at 5µl/min, 97% Buffer A (100% water, 0.1% formic acid) for 3 min. Peptide separation
was performed at 330 nl/min with Buffer A: 100% water, 0.1% formic acid and Buffer B: 100%
acetonitrile, 0.1% formic acid. A linear gradient (90 minutes) was run with 3% buffer B at initial
conditions; 5% B at 1 minute; 35% B at 50 minutes; 50% B at 60 minutes; 90% B at 65-70; and
back to initial conditions at 71 minutes. MS was acquired in profile mode over the 300-1,700 m/z
range using 1 microscan; 70,000 resolution; AGC target of 3E6; and a full max ion time of 45 ms.
MS/MS was acquired in centroid mode using 1 microscan; 17,500 resolution; AGC target of 1E5;
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full max IT of 100 ms; 1.7 m/z isolation window; normalized collision energy of 28; and 2002,000 m/z scan range. Up to 20 MS/MS were collected per MS scan on species with an intensity
threshold of 2E4, charge states 2-6, peptide match preferred, and dynamic exclusion set to 20
seconds.
LC-MS/MS on the Thermo Scientific Orbitrap Fusion. LC-MS/MS analysis was
performed on a Thermo Scientific Orbitrap Fusion equipped with a Waters nanoAcquity UPLC
system utilizing a binary solvent system (Buffer A: 100% water, 0.1% formic acid; Buffer B: 100%
acetonitrile, 0.1% formic acid). Trapping was performed at 5µl/min, 97% Buffer A for 3 min using
a Waters Symmetry® C18 180µm x 20mm trap column. Peptides were separated using an
ACQUITY UPLC PST (BEH) C18 nanoACQUITY Column 1.7 µm, 75 µm x 250 mm (37ºC) and
eluted at 300 nl/min with the following gradient: 3% buffer B at initial conditions; 5% B at 5
minutes; 20% B at 90 minutes; 35% B at 125 minutes; 97% B at 130 minutes; 97% B at 135 min;
return to initial conditions at 136-150 minutes. MS was acquired in the Orbitrap in profile mode
over the 300-1,500 m/z range using quadrupole isolation, 1 microscan, 120,000 resolution, AGC
target of 4E5, and a maximum injection time of 60 ms. MS/MS were collected in top speed mode
with a 3s cycle time on species with an intensity threshold of 5E4, charge states 2-8, peptide
monoisotopic precursor selection preferred. Dynamic exclusion was set to 30 seconds. Data
dependent MS/MS were acquired in the Orbitrap in centroid mode using quadrupole isolation
(window 1.6m/z), HCD activation with a collision energy of 28%, 1 microscan, 60,000 resolution,
AGC target of 1E5, maximum injection time of 110 ms.
Peptide Identification. Data was analyzed using Proteome Discoverer software v2.2
(Thermo Scientific). Data searching is performed using the Mascot algorithm (version 2.6.0)
(Matrix Science) against the SwissProtein database with taxonomy restricted Homo sapiens. The
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search parameters included tryptic peptides with up to 3 missed cleavages, 10 ppm precursor mass
tolerance and 0.02 Da fragment mass tolerance, and variable (dynamic) modifications of
methionine oxidation, carbamidomethylated cysteine, deamidated asparagine or glutamine, and
citrullination of arginine. Normal and decoy database searches were run, with the confidence level
set to 95% (P < 0.05). Scaffold (version Scaffold_4.8.7, Proteome Software Inc., Portland, OR)
was used to validate MS/MS based peptide and protein identifications. Peptide identifications were
accepted if they could be established at greater than 95.0% probability by the Scaffold Local FDR
algorithm. Protein identifications were accepted if they could be established at greater than 99.0%
probability and contained at least 2 identified peptides.
Quantitative Real-time Polymerase Chain Reaction (qRT-PCR). Total RNA was
isolated from saline-perfused unfixed whole brain tissue using TRI Reagent (Sigma) according to
the manufacturer’s protocol. cDNA was amplified using the iScript kit (BioRad) and qPCR was
performed using specific validated primer pairs for Cxcl10 and Ccl2 (Integrated DNA
Technologies, Coralville, IA) and using the SsoAdvanced™ Universal SYBR® Green Supermix
(BioRad) according to the manufacturer’s protocol. Target cDNA was amplified and analyzed by
the CFX Connect™ Real-Time PCR Detection System (BioRad). Primers for β-actin were used
to assess the general expression level of the housekeeping gene among samples. The relative
expression of target RNA was calculated using the comparative cycle threshold analysis (ΔΔCT).
Statistical analysis. Data were analyzed by two-way ANOVA with uncorrected Fisher’s
LSD post-hoc test or non-parametric Mann-Whitney U-test as indicated using GraphPad Prism
version 7 for MAC OS X (GraphPad Software, La Jolla, California, USA). Differences were
considered significant when P < 0.05. Data are presented as mean ± s.e.m.
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IV. Results
Plasma EVs induce spontaneous relapses in EAE mice.
EAE immunization in mice on the C57BL/6 background induces a robust and consistent
monophasic clinical disease course mediated by a prominent CD4+ lymphocyte activation (386,
393). pEVs isolated from stored red blood cell units have been found to bind to monocytes and
induce pro-inflammatory cytokines, which boosts CD4+ and CD8+ T cell responses in vitro (315).
Additionally, EVs are capable of augmenting pre-existing inflammatory responses in vivo (394).
Whether and how pEVs can augment the neuroinflammatory events in EAE have not been
previously examined. To determine if pEVs can augment the inflammatory response in EAE mice,
we first isolated and confirmed the presence of EVs from mouse blood-plasma. The purity of
isolated pEVs was verified by electron microscopy (EM), an approach to validate EVs we have
used previously (307) (Figure 1B). To determine the effect pEVs have on the EAE disease course,
MOG-EAE immunized mice received a single injection of pEVs at the time of peak clinical
disability (Figure 1A). We found that pEV-injected MOG-EAE mice developed a worsened
pattern of EAE with clinical disability characterized by spontaneous relapses with remissions
(R/R) that were not observed in control EAE subjects (Figure 1C-D). These findings are consistent
with a previous report that permutations of MOG-EAE in C57BL/6 mice can evoke a relapsingremitting disease phenotype (395).
pEVs induce CD8+ T cells.
To determine whether and how pEVs evoked neuroinflammatory changes within the CNS of EAE
mice, we next analyzed expression of the Fb-inducible chemokines Ccl2 and CXCL10 in brain
tissues of R/R EAE (pEV administered) mice during a first relapse event. Ccl2 and CXCL10 levels
were found to be increased in the brain during relapse of pEV-treated R/R mice (Figure 2A). Since
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these two chemokines are known to promote Fb-induced T cell and macrophage recruitment into
the CNS (396), we examined the composition of the immune cell infiltrates in the brains of pEVadministered EAE mice during a relapse. To explore this question, we applied an unbiased survey
of immune cells by using flow cytometry by time of flight (CyTOF) and applied T-distributed
stochastic neighbor embedding (t-SNE) analysis of all labeled CNS immune cells. This approach
identified a specific increase in CD3+/CD8+ T cells in pEV-administered, R/R-EAE mice (Figure
2B). Since autoimmunity in MOG35-55-EAE mice is typically driven by CD4+ T cells (162), we
next established the contribution of CD8+ T-cells to R/R EAE mice by immunodepletion of CD8+
cells from R/R mice (Figure 2C). Administration of anti-CD8 antisera was found to prevent the
relapsing activity phenotype in response to pEV administration in treated mice (Figure 2D-E).
Anti-CD8 antisera did not affect disease in control EAE mice not given pEVs (data not shown),
nor did an Ig-matched control antisera change disease exacerbation activity in treated R/R mice
(Figure 2D-E). Hence, pEVs induced a robust CD8+ T cell response which was required for the
relapsing-remitting phenotype in treated EAE mice.
Fibrinogen mediates relapse inducing action of pEVs.
Proteomic analysis of the pEVs was performed using the two-dimensional protein
fractionation platform (PF-2D; Figure 3A). Proteome lab identification of enriched fractions were
interrogated by LC/MS/MS. These fractions identified a limited number of candidate factors
(Supplementary Table 1), which included fibrinogen alpha chain (FGA). As a candidate pEV
factor, fibrinogen (Fb) was of particular interest because Fb deposition occurs with vascular
leakage and promotes T cell recruitment, CNS demyelination, and axonal damage (397).
Immunoblotting and EM confirmed pEV expression of the EV marker, flotillin-1 (Figure 3B), and
co-localization of Fb in the pEVs (Figure 3C). To determine whether Fb was a necessary cargo of
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pEVs to induce R/R in MOG-EAE mice, pEVs were collected from fibrinogen knockout (Fib-/-)
mice and wild-type littermate (Fib+/+) controls (Figure 3D). When the Fib-/- pEVs were
administered to MOG-EAE mice, these mice did not develop any change in typical EAE course
(Figure 3E-F), while administration of Fib+/+ pEVs induced the R/R clinical phenotype with
disease exacerbation as observed with other wildtype pEV donor blood samples (Figure 3E-F).
These data determined that Fb in pEVs was required to induce a pattern of spontaneous relapsingremitting activity in EAE mice.
Citrullinated Fb Identifies EVs from MS Patients.
To determine whether pEVs from human blood, including in MS patients, also contained
Fb we performed a proteomic analysis of pEVs from non-diseased subjects and patients with
RRMS. LC-MS/MS of the pEVs also identified Fb in human pEVs (Supplementary Table 2).
We validated isolation of pEVs and confirmed the presence of Fb in these pEVs by
immunoblotting using plasma-isolated human Fb as a positive control (Figure 4A and B). No
apparent differences in the Fb peptide fragments were identified when comparing RRMS with
control pEV samples, however, recent studies have pointed to post translational modifications of
peptides through citrullination as a disease-associated process (62, 398, 399). Indeed, citrullination
has been reported to promote autoimmunity, and in response to demyelination, citrullination of
myelin peptides has been recently shown to initiate neuroinflammation (62). To address this
possibility, we then performed LC-MS/MS analysis on an Orbitrap mass spectrometer to identify
post-translational modifications on peptides of the same pEV samples. This identified a short list
of citrullinated peptides in pEVs (Supplementary Table 3). Of these, citrullinated Fb peptide
sequences were identified on alpha, beta, and gamma chains in RRMS and control pEV samples
(Supplementary Figure 1 and Table 4). An analysis of citrullinated peptide motifs in Fb of
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RRMS and control pEV samples revealed preferential modification of arginine preceding proline
unique to the RRMS pEVs samples (Figure 4C). This motif may represent a difference in the
recognition and/or potential functional impact of these citrullinated motifs of Fb related to RRMS
disease (400). Moreover, our data extend upon previous findings in other human diseases by
having identified citrullinated peptides of Fb in pEVs.
V. Discussion
In this report, we demonstrate a novel mechanism to induce and study encephalitogenic
CD8+ T cells in the widely used MOG35-55-EAE mouse model of multiple sclerosis (MS). We
show that plasma extracellular vesicles (pEVs) administered at the time of peak of clinical disease
in mice with active EAE resulted in the development of a unique phenotype of spontaneous
relapsing-remitting disease - a clinical feature not generally observed in this MOG35-55-EAE mouse
model. Using a top down-proteomic approach to interrogate pEVs we identified fibrinogen as the
component of pEVs responsible for inducing CD8+ T cell-mediated spontaneous relapses.
CD8+ T cells are the predominant T cell subtype found within active lesions in RRMS
patients, which are posited to be the primary cellular mediators of CNS injury during relapse events
(401, 402). Despite this, the most widely studied mouse model of MS, MOG35-55-EAE, induces a
prominent CD4+ T cell driven disease (96). While this model has provided insights into the
immunology of MS, salient features such as the paucity of CD8+ T cells in this model has limited
detailed exploration on the role of CD8+ cells as a key feature of the human disease. Our study
applied CyTOF analysis to identify which immune cells in pEV-treated MOG35-55-EAE mice
contributed to the relapsing phenotype and determined that immunoblocking of the striking
elevation in the proportion of CD8+ T cells in the pEV-treated mice prevented the relapsing
phenotype. These data further strengthen the argument for CD8+ T cells as a driver of relapsing102

remitting disease. Moreover, the widespread elevated expression of MHC class I antigens in active
lesions in acute and chronic MS (115, 118) suggest a pervasive role for cytotoxic CD8+ T cells in
the MS brain that can ostensibly be better studied using the pEV-R/R-EAE model. Of particular
interest to demyelination, oligodendrocyte-specific autoreactive CD8+ T cells have been found to
lyse oligodendrocytes in vitro and CD8+ T cells from MS patients have been found to secrete toxic
factors, such as lymphotxin, that are damaging to oligodendrocytes (403, 404). While our data
would place pEVs as a proximal cause of encephalitogenic CD8+ T cells in disease, future studies
will be needed to resolve the identities and specificities of the CD8+ T cell population(s) resulting
from the initiation of CD8-mediated immunity in this model.
Based on our findings, we would also postulate that pEV-associated fibrinogen may
contribute to HLA class I linkage disequilibrium and increased susceptibility for autoimmunity,
which has been identified in human MS (405). Our data support accumulating evidence that now
point to fibrinogen as an important disease-related trigger for the development of an
encephalitogenic adaptive immune response associated with CNS demyelination with striking
features similar to those observed in human MS (396, 397). Fibrinogen is known to be a critical
component of the blood coagulation cascade that is cleaved into fibrin to stabilize the formation
of blood clots. Interestingly, due to its unique molecular structure, binding sites on fibrinogen for
receptors expressed by CNS cells, such as astrocytes, oligodendrocytes, and microglia, and for
proteins (e.g., TGFβ and Aβ) have been found to regulate key nervous system functions (397, 406).
The study of extracellular vesicle (EV) biology and function is a rapidly growing field of
active research. EVs are membrane-bound organelles that are released from tissues containing a
diverse array of molecular cargo (e.g., RNA, protein, and metabolites) (407). EVs have been
identified in many different biofluids, including blood-plasma. The functional relevance of the
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release of EVs into circulation in the broad contexts of health and disease is an area of continuing
investigation. Our data suggest that pEV function is at least partially reliant upon its EV proteome.
Indeed, previous studies have shown RNA and even protein transfer as a consequence of
intercellular communication by EVs (407). Within the specific context of active inflammatory
disease, pEVs when administered to mice with active MOG35-55-EAE led to the development of a
spontaneous relapsing phenotype that was dependent upon pEV fibrinogen. This result is
consistent with previous findings that fibrinogen-deficient plasma when injected into the brain
parenchyma did not induce an encephalitogenic T cell response when compared to fibrinogen-rich
plasma (396). That pEVs are a source of fibrinogen and also potent effectors of fibrinogen's effects
on inflammation under disease conditions is a striking but not unexpected result. In cancer, MHC
class I and MHC class II complexes on EVs have been shown to carry tumor or pathogenic peptides
that can stimulate CD4+ or CD8+ T cells directly, as well as indirectly through interactions with
APCs (389). Additionally, EVs can transfer both antigens and signals to APCs to promote their
activation into immunogenic APCs (261). Given the diverse potential effector functions of EVs on
the activity of the immune cells, our findings provide additional evidence for pEVs as modulators
of the autoimmune response in multiple sclerosis. While we have determined that pEV fibrinogen
can evoke CD8+ T cells, we do not know the precise mechanism by which EV-associated
fibrinogen achieves this effect. Moreover, our analysis of pEVs from healthy human donors and
from MS patients would suggest that in patients, it is not fibrinogen itself but its post-translational
modification (PTM) that makes this protein of particular interest in the context of autoimmunity
and immune-mediated pathology in MS.
Identification of citrullinated peptides in pEVs, in the context of the dysregulated immune
responses in MS, support a growing awareness that PTMs contribute to the repertoire of peptides
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in the plasma (pEV) and represent an important component to understand disease pathogenicity
(Figure 4D). Citrullination, or deimination, is a process by which a guanidine group of arginine is
hydrolyzed to a ureido group and ammonia that produces a deiminated amino acid called citrulline
(408, 409). This PTM of arginine to citrulline is carried out by a family of five citrullinating
enzymes known as peptidylarginine deiminases (PADs). Of the PAD family proteins, PAD2 and
PAD4 are present in brain tissue and upregulated in the CNS in EAE (408, 409). Additionally, a
number of PAD substrates have already been identified, including GFAP (410), MBP (411),
nuclear proteins (412), and CXC chemokine family members (413). The robust fibrinogen-evoked
CD8+ T cell response is analogous to a delayed-hypersensitivity type III response similar to the
role of citrullinated fibrinogen in promoting T cell driven autoimmunity in rheumatoid arthritis
(RA) (414, 415). While there are known MHC II susceptibility genes in MS that point towards
CD4+ T cells as the master driver of disease progression, it is well known that CD4+ T cells prime
CD8+ T cells for effector function (115). Therefore, the presence of citrullinated fibrinogen
peptides under normal, non-diseased conditions would not itself be antigenic, however, if present
during active inflammation, the antigenicity of citrullinated peptides may serve to exacerbate the
inflammatory response. Specifically, citrullination results in the loss of a positive charge which
can evoke altered secondary and tertiary structures of the proteins, which can result in enhanced
antigenicity of peptides (408, 409). Our data would implicate PAD enzyme functions in the
citrullination of fibrinogen in pEVs in MS which may contribute, by yet undefined mechanisms,
to foster development of autoreactive CD8+ T cells driving neuroinflammation.
In summary, our findings on the elucidation of pEV-mediated CD8-driven immunity in
EAE provides unique insights into plausible mechanisms by which endogenous blood factors can
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drive encephalitogenic T cell responses in MS. Continued study of this pEV-EAE model may be
expected to elucidate the etiology of relapse activity in human RRMS (118, 416).
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VII. Figures
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Figure 4-1: pEVs induced a spontaneous relapsing-remitting phenotype in wild-type
C57BL/6 mice during MOG35-55-induced EAE. (A) pEVs isolated from donor mouse plasma
[were confirmed by transmission electron microscopy shown in (B)], or vehicle were administered
(i.v.) to EAE mice at peak clinical illness (arrow). (C) Representative clinical EAE disease courses
in pEV and vehicle-treated mice. (D) Grouped treatment effect over 51-day experimental period
of vehicle and pEV-treated MOG35-55-EAE mice (n=6/group). Scale bar is 100nm. Values are mean
± s.e.m., where ****P < 0.0001 and *P < 0.05 calculated by two-way ANOVA with uncorrected
Fisher’s LSD post-hoc test.
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Figure 4-2: pEVs induce a CD8+ T-cell response responsible for the development of a
spontaneous relapsing phenotype in MOG35-55-EAE. (A) Expression of chemokines Ccl2 (n =
3) and Cxcl10 (n = 3) was significantly up-regulated at time of a spontaneous relapse in the brains
of pEV-R/R mice. (B) CyTOF analysis of brains of R/R mice identified unique CD8+ T cell
population. (C) EAE in pEV-treated EAE mice also given αCD8 function blocking antibody or
isotype antisera, and (D) representative clinical disease courses in individual treated mice, and
plotted as group (E) (αCD8; n = 8; isotype control, n = 7). Values are mean ± s.e.m., where ****P
< 0.0001 and *P < 0.05 calculated by two-way ANOVA with uncorrected Fisher’s LSD post-hoc
test; *P < 0.05 (Mann-Whitney test).
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Figure 4-3: pEV fibrinogen is necessary to induce a spontaneous relapsing-remitting
phenotype in wild-type C57BL/6 mice during MOG35-55-induced EAE. (A) Topographic plot
of proteomic (PF-2D) analysis of mouse pEVs and identified fractions for MS/MS peptide
identification. Immunoblotting (left) and immuno-EM (right) confirmed EV marker (B) flotillin1 (48 kDa) and (C) blood coagulation factor fibrinogen alpha (63.5 kDa), beta (56 kDa), and
gamma (47 kDa) chain expression on pEVs as confirmed by plasma-isolated murine fibrinogen
immunoblotting. (b’ and c’) Secondary-only immuno-EM of pEVS. (D) Clinical effect of pEVs
isolated from Fib+/+ or Fib-/- mouse plasma when injected (i.v.) into MOG35-55 EAE mice at peak
clinical illness. (E) Representative clinical disease course of individual mice MOG-EAE mice
administered Fib+/+ or Fib-/- pEVs. (F) Grouped treatment effect data of Fib+/+ pEVs and Fib-/pEV-treated mice (n = 6-9/group). Scale bars are 100nm. Arrows indicate α-fibrinogen and αflotillin-1 gold particles. Values are mean ± s.e.m., where ****P < 0.0001, **P < 0.01, and *P <
0.05 calculated by two-way ANOVA with uncorrected Fisher’s LSD post-hoc test. Fib+/+ denotes
wild-type littermate mice and Fib-/- denotes fibrinogen knock-out mice.
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Figure 4-4: Proteomic analysis of pEVs from RRMS patient samples identified a unique
citrullination peptide motif. Immunoblotting confirmed EV marker (A) flotillin-1 and (B)
fibrinogen alpha chain on human pEVs (n = 3/condition) as confirmed by plasma-isolated human
fibrinogen. (C) Motifs of citrullination differed in non-diseased (upper) and RRMS (lower) patient
pEVs. (D) Proposed model for pEV Fb promoting CD8+ T-cell mediated relapses and
inflammation associated with CNS demyelination.
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Chapter 5: Discussion and Future Directions
Growing interest into the multifactorial roles of extracellular vesicles (EVs) in health and
disease has grown almost exponentially over the last 20 years. More specifically, this growing
interest has spread to understanding EVs in the context of normal brain functioning and during the
course of neurological diseases and disorders. In my thesis, I explored how EVs could act as a
biomarker of disease exacerbation in MS and their ability to modulate the disease course. My data
found that astrocyte-derived EVs are a potential source of biomarkers within the blood that can be
utilized to track the disease status of MS patients. Additionally, I found that plasma EVs are
capable of inducing a dramatic relapsing-remitting phenotype via the presence of the blood
coagulation factor fibrinogen being in close association with these EVs.
Although my thesis was focused on EVs in MS, the findings can broadly be applied to a
variety of CNS disorders where astrocytes and blood-borne factors can influence the disease
course. Further, interrogating the EVs of other CNS cells, such as microglia and oligodendrocytes,
may provide a unique approach to understanding the changes that occur in these cells during
disease and provide new targets for biomarker development.
I. Astrocytes and Exosomes
Astrocytes have long been considered part of the “glue” that provides structure to the brain,
however this passive view of these cells has been challenged over the last 20 years and we now
know that astrocytes are an extraordinarily dynamic and heterogenous cell population within the
CNS (417). This is of particular importance in diseases of the CNS as astrocytes can have both
positive and negative effects in modulating the extracellular environment (348, 362, 418). One
potential source of extracellular regulators are EVs. A quickly growing field that is encompassing
all facets and manners of human disease, EVs can induce critical and significant changes in host
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and target cells to drive or negate pathology (262, 282, 314). However, directly linking the cellular
source of EVs to pathological or protective responses in vivo is a challenging endeavor due to the
innate heterogeneity of EVs in biofluids, lack of cell-specific markers that can recognize EVs, and
disparate methods of isolation and characterization (212, 331, 388).
In an effort to tackle these inherent problems in studying EVs, the first part of my thesis
was directed at establishing a new and reliable method for the isolation and semi-quantitative
analysis of astrocyte-derived exosomes from both in vitro and in vivo settings (307). For the
isolation of exosomes in this study I used two, well-established methodologies: the commercially
available ExoQuick-TC™ precipitation kit and a differential ultracentrifugation protocol (218). It
should be noted there are limitations to using both of these methods including: (1) incomplete
isolation of all exosomes, (2) presence of precipitate in isolated fractions, (3) and contamination
of pellets with cellular debris, proteins, and larger vesicles. However, it is currently impossible in
the field of EV biology to eliminate all of these caveats, rather the goal is to focus on minimizing
the potential for contamination. I also employed the use of FACS to semi-quantitatively analyze
exosomes from culture media and blood-serum. Flow cytometry is a gold-standard for the
detection and quantification of physical and chemical characteristics of populations of cells or
particles. Despite this, there are inherent problems in using FACS analysis to quantify exosomes.
As stated in chapter two, exosomes are nanosized vesicles roughly 50-150nm in size. The
fluorescence detectors on flow cytometers are designed for the purposes of analyzing cells, which
can be anywhere from 1 µm to 100 µms in size, with a lower limit of detection at 200 nm (personal
communication with the director of the Flow Cytometry Core, Evan Jellison). Therefore, to bridge
this gap, I developed a methodology that would allow for not only the detection of exosomes at
this lower limit of detection, but also for the semi-quantitative analysis of exosome numbers and
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the specific isolation of astrocyte-derived exosomes. I used the stereotypical astrocyte marker
GFAP in tandem with the canonical exosome markers TSG101 and CD63 to (1) determine if
astrocytes released more exosomes following IL-1β cytokine challenge and (2) if astrocytes
released more exosomes into peripheral circulation during the EAE disease course. My findings
of increased exosome release following cytokine challenge and during the peak of clinical
disability in EAE animals was the first report to my knowledge addressing these questions (307).
As a note, I will be using EV from this point forward rather than exosome to maintain clarity
throughout the rest of the discussion.
BBB breakdown is a common feature associated with MS, as well as other
neurodegenerative diseases (419, 420). Astrocyte endfoot processes form close associations with
the basement membrane of endothelial cells to form the glia limitans, which prevents and regulates
the free movement of small molecules and cells into the brain parenchyma (421). In EAE, the
animal correlate of MS, BBB breakdown and leakage has been found to occur (422). In my own
study, I found that GFAP-positive astrocyte-EVs were readily detected in peripheral circulation in
EAE and control animals prior to clinical onset but significantly increased at the height of clinical
disability (307). At the time of publication of this study, we were unsure what role astrocyte EVs
played in the EAE disease process, if any. However, a study from Dickens et al. two years later
identified one possible role. In this study, it was observed that intrastriatal administration of IL-1β
resulted in an increase of EVs in peripheral circulation (423). The authors then isolated plasma
EVs from these mice and infused them intravenously into recipient mice where they observed an
ACR in the liver and the transmigration of leukocytes to the brain parenchyma. Since astrocytes
have an intimate association with the BBB and based on observations that astrocytes release more
EVs following IL-1β stimulation compared with microglia, the authors infused EVs isolated from
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IL-1β treated astrocytes in vitro into mice. This resulted in a peripheral ACR and transmigration
of leukocytes into the brain parenchyma, providing proof-of-concept that cytokine-induced
astrocyte-EVs are capable of initiating an immune response that seems to be driven by the liver
(423). This also fits nicely with, and corroborates, my in vitro findings of an increased release of
EVs from astrocytes treated with IL-1β (307). The identification of an astrocyte-liver-brain axis
as a form of communication between the CNS is periphery, coupled with my findings of increased
astrocyte-EVs in EAE points to a larger role of the CNS directing and regulating the immune
response to brain injury. Pursuing additional mechanisms and investigating other peripheral organs
where astrocyte-EVs have been found to travel (e.g., lung and spleen (423)) will fill in critical gaps
in our knowledge and may provide for novel therapeutic targets in treating MS and other
neurodegenerative diseases with BBB disruption.
It has been noted that astrocyte-derived EVs can be detected in peripheral circulation under
non-diseased conditions since it is well established that BBB breakdown and permeability
increases under neurodegenerative diseases (420). The dogma surrounding the BBB as a solid
barrier between the periphery and nervous system would inform us that any EVs released by neural
cells would be either restricted to the CNS compartment or contained within the CSF. Therefore,
determining why astrocytes, and potentially other neural cells, release EVs into the peripheral
circulation under non-diseased conditions is a compelling area for future studies. The use of
fluorescence reporter mice tagged to known EV proteins has been utilized for not only tracking
EVs in vivo but also to identify the cellular and tissue-specific localization of specific EV
populations (423, 424). Using cell-specific fluorescence, then, could be a powerful tool to identify
the target cells of neural-cell derived EVs (and vice-versa), which could provide compelling

119

evidence of a significant cross-talk between the CNS and periphery in monitoring and regulating
normal, everyday functioning.
However, this should not overshadow the importance of understanding the functional
consequences of astrocyte-EVs in the healthy CNS. The known roles of astrocytes in maintaining
normal CNS functioning has been discussed extensively in Chapter 1, however there is a critical
gap in our knowledge regarding the role(s) astrocyte EVs play in this maintenance. For example,
I have found that astrocyte-derived EVs promote the differentiation and maturation of rat OPCs,
whereas EVs derived from astrocytes following IL-1β cytokine challenge inhibit this maturation
(Figure 5-1). This identifies a potential role for astrocyte EVs in OPC maturation not only in the
developing CNS, but also following tissue damage and injury. Future studies using state-of-the art
techniques in fluorescence imaging and microscopy, such as fluorescence resonance energy
transfer (FRET) or super-resolution microscopy, respectively, could help to identify unique
populations of astrocyte EVs and their cognate receptors that will allow for a more thorough
understanding of the functional and mechanistic roles these vesicles play. Additionally, future
studies analyzing and characterizing the proteomic, RNA, and lipidomic content of astrocyte EVs
would allow for the development of a detailed EV interactome. The information gathered in this
astrocyte-EV interactome would give researchers a foundation to develop novel hypotheses to
elucidate the contribution of astrocyte EVs in maintaining normal brain functioning.
The pursuit of discovering biomarkers for tracking and monitoring disease progression is
an active and growing field. As EVs are readily isolated from many biofluids using non-invasive
procedures, they are attractive candidates for biomarker discovery (425, 426). The identification
of astrocyte GFAP in association with EVs in blood from my own work, in addition to the work
by Dickens et. al. to identify a mechanism of action for these EVs points to the potential future
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development of GFAP-EVs as a biomarker in MS. However, further steps must be taken to validate
astrocyte-EVs as biomarkers in this disease. Future studies identifying additional astrocyte
markers, such as aldehyde dehydrogenase 1 (aldh1l1) or glutamate aspartate transporter (GLAST),
on EVs and whether the expression of these proteins on EVs changes during the course of disease
is warranted. One such way to perform this would be to gather blood samples from cohorts of
healthy and RR-MS patients over a set time span of the disease to monitor changes in GFAP-EV
levels (or in conjunction with other known candidate astrocyte markers) and correlate any
identified changes with disease exacerbations (i.e. relapses) or worsening clinical disability. If any
noticeable patterns were to arise, efforts would have to be made to streamline the isolation and
characterization of blood EVs. This would entail the design of a rapid, reliable, and reproducible
method of EV isolation for downstream characterization, as the current gold standard in the field,
differential ultracentrifugation coupled with density gradient separation, is time-consuming and
requires specialized pieces of equipment. There are numerous commercially available EV isolation
kits, however these kits can be cost prohibitive and suffer from insufficient yield, low purity, and
lack of consistency (427). However, the far bigger issue with using EVs as biomarkers is the
complete lack of a consensus method for the absolute quantification of EV number from the source
biofluid. The most widely used quantification method involves the use of a nanoparticle analyzer.
These instruments use the brownian motion of particles in a fluid to determine the concentration
and size of EVs in a sample. Despite the ability of these instruments to quantitate the number of
EVs in a given sample, the machines are costly, require training, and involve extensive calibration
of the instrument for optimal performance. Therefore, the use of semi-quantitative methods, as
detailed in my study, could provide an alternative method for detecting changes in EV levels. Flow
cytometry analysis is currently used as a way to characterize diseases in a clinical setting (428,
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429), therefore adapting methodologies developed in biomedical research for use in the clinics
with access to flow cytometers is an attractive avenue. The field of EV biology is in its infancy,
however studies extensively characterizing EVs from specific cell types coupled with
improvements in technologies aimed at quantifying EVs will hopefully one day lead to the first
EV biomarker to be used in a clinical setting.
II. Plasma EVs and Relapsing-Remitting Multiple Sclerosis
There is growing interest into understanding how factors present in blood-plasma
fundamentally contribute to the immune activation and neurodegeneration associated with many
neurological disorders. This is due to the significant structural changes that are known to occur at
the neurovascular interface during active neurological disease, which leads to an influx of plasma
proteins into the CNS thereby disrupting the homeostasis between the vasculature and the CNS
(397, 430). One major plasma protein that has been studied for its causal role in MS pathology, as
well as many other neurodegenerative diseases, has been fibrinogen, which is involved in the blood
coagulation cascade (397). Briefly, in tissue or vascular injury fibrinogen is enzymatically
converted by thrombin to fibrin, which forms the basis of fibrin-based blood clots. However,
fibrinogen is also considered ‘positive’ acute-phase protein, meaning the levels of fibrinogen
increase in response to systemic inflammation, tissue injury, and various other events (66). This is
of particular relevance to MS, as increased tissue injury (e.g. BBB breakdown and lesion
formation) and systemic inflammation are strong drivers of the disease pathology and progression
(31, 431). In fact, it has already been shown that intracerebral injections of fibrinogen into the CNS
can promote an autoimmune response with associated demyelination that has pathological
correlates to the human condition (396). Therefore, understanding how fibrinogen contributes to
the pathogenesis of MS is an area of active research.
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In my own thesis studies, I have found that fibrinogen is associated with EVs isolated from
blood-plasma (pEVs), and that it is capable of inducing a relapsing-remitting phenotype in an EAE
mouse model of MS disease (see Chapter 4). However, I was not able to fully elucidate the
mechanism wherein these pEVs induced the relapsing-remitting phenotype. I had performed
CyTOF (i.e. mass cytometry) and identified an increase in CD8+ T cells in EAE mice receiving
pEV injections versus PBS injected controls. This fits with prior findings of increased CD8 T cells
in RRMS patients (118), however CD8 T cells are a heterogenous population (432) and future
studies in the lab will need to focus on identifying which population(s) of CD8 T cells are
responsible for driving these relapses. CyTOF is a powerful tool that can be used to identify unique
groups or populations of cells and would be indispensable in helping to identify the critical CD8
population driving the relapses observed in my studies. Additionally, if a group of CD8 T cells
were shown to be differentially activated in pEV-injected EAE animals, traditional FACS of this
population followed by RNA-sequencing could allow for a mechanistic understanding of the
changes in these cells that drives the phenotype. RNA-seq coupled with proteomic analysis could
then allow for the analysis of critical pathways that drive the positive or negative regulation of
these cells that could be targeted for therapeutic intervention to dampen their activation.
The identification of cellular sources of EVs from complex biofluids, such as plasma, are
extraordinarily difficult given our current technical limitations and biological understandings in
regards to EV characterization. However, based on a priorii knowledge, I would estimate a large
portion of circulating EVs, including fibrinogen-associated EVs, are derived from platelets given
their critical importance in producing and directing blood clotting (433). However, to my
knowledge, no attempts at EV characterization of blood-plasma has been performed. Therefore,
future studies using CyTOF coupled with proteomic, miRNA, and RNA-sequencing analysis of
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plasma EVs could lead to a more holistic understanding of the make-up of plasma EVs and lead
to the identification of EVs from other cellular sources. This would be a challenging endeavor and
may not lead to a full understanding of the complexity of plasma EVs, but given my development
of a methodology to isolate specific EV populations from blood and the analytical power of mass
cytometry, findings from such a study could provide a small peek into the representative EV
populations present in plasma.
I have already outlined a need in the first part of my discussion to identify the cellular
targets of astrocyte-derived EVs. That line of thinking is also applicable to this portion of my thesis
studies. While it would be impractical, if not impossible, to use transgenic animals to identify and
track the biodistribution of EVs in peripheral circulation, ex vivo labeling of EVs through panlipophilic dyes is an attractive alternative. This process involves the isolation of EVs from plasma
followed by labeling with a near-infrared lipophilic dye (DiI; Invitrogen) that can intercalate into
the membranes of EVs, allowing for in vivo analysis of EV trafficking and biodistribution using
an in vivo imaging system (IVIS Spectrum In Vivo Imaging system, PerkinElmer) (434).
Preliminary results from labeling experiments I performed, wherein I intravenously injected DiI
labeled plasma EVs into a normal wild-type mouse and mouse with active EAE, identified a
preferential biodistribution of EVs to the brain and liver (Figure 5-2). This is of particular interest
based on the study I had previously discussed identifying the liver as one potential peripheral organ
that could be driving immune activation directed at the CNS (423). Further studies using in vivo
imaging would require extensive immunohistochemical analysis of tissue sections from both the
brain and liver to identify the preferential trafficking of plasma EVs to tissue-resident cells. These
studies could also be supplemented with proteomic and genomic analysis of targeted cells to
identify activity changes in critical pathways known to drive immune activation. Further, in vitro
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assays of tissue-specific cells, such as ELISA for secreted factors and immunocytochemistry using
flow cytometry for intracellular production of cytokines and chemokines would provide crucial
information on how the liver is capable of shaping an immune response that targets the CNS. One
known receptor for fibrinogen is CD11b/CD18, which is present on macrophages and CNSresident microglia (396). Fibrinogen interacting with this receptor is thought to drive the
autoimmune response observed following intracerebral injection of fibrinogen (396). Future
studies, however, will need to further investigate whether EV-bound fibrinogen has a similar
affinity for the CD11b/CD18 receptor or if there is preferential trafficking to other CNS resident
cells, such as oligodendrocytes, astrocytes, and/or neurons. In regards to astrocytes, it has been
found that fibrinogen can trigger astrocyte scar formation (435) and that astrocytes can specifically
take-up and remove fibrinogen (436). However, future studies investigating these aspects in an
EAE animal need to be actively pursued, as well as investigating whether astrocytes have similar
capacities in EAE animals following pEV injections.
An area of active and growing research is focused on the role of post-translational
modifications (PTM) as a contributor to inflammation and autoimmunity. PTMs can promote the
generation of neo-(auto)antigens, which can lead to the generation of an autoimmune response in
subjects with a pre-disposed reduction in self-tolerance, such as patients with MS and rheumatoid
arthritis (RA) (30, 437, 438). One such PTM, citrullination, has garnered great interest due to its
presence in a wide range of inflammatory tissues (438). Citrullination, also known as deimination,
is the conversion of the amino acid arginine in a protein into the amino acid citrulline through
enzymes called peptidylarginine deiminases (PADs) (411). As a result, citrullinated proteins can
become antigenic and lead to the immune system to mount an autoimmune response to these selfpeptides through the production of autoantibodies (411). Citrullinated MBP (439) and GFAP (410)
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have already been identified as possible antigenic targets in MS that can be readily focused by the
immune system. Fibrinogen can also undergo citrullination and autoantibodies directed against
citrullinated fibrinogen has strong diagnostic, predictive, and prognostic value for RA, where it
has been extensively studied (438). Since citrullination can lead to a strong autoimmune response,
part of my thesis studies involved PTM analysis of pEVs from healthy and RRMS patients. I found
that, indeed, fibrinogen is citrullinated in both patients, however there seemed to be a
conformational shift in the protein structure of pEV-bound fibrinogen that could expose the
citrullinated peptide making it an antigenic target by the immune system (See Chapter 4). Given
this finding, it would be necessary in the future to determine if there was generation of
autoantibodies against citrullinated fibrinogen in these animals, as is observed in RA. If such a
finding were to occur, then therapeutics directed against citrullinated fibrinogen could be tested in
EAE animals following pEV injections to determine if this is an effective strategy for dampening
the immune response I have observed. Additional studies could investigate whether the
citrullinated peptide sequences in fibrinogen are specific to MS patients versus healthy controls.
There could be preferential citrullination of targeted fibrinogen sequences in MS patients that
renders them more susceptible to loss of self-tolerance and the generation of an autoimmune
response. This is a complex route to take, however, due to the high variability in pathological
presentation of MS. There is also the concern that citrullination may only be affecting a small
subset of the overall MS patient population, rendering this line of investigation susceptible to a
‘fishing expedition’ or chasing a needle in a haystack. Should specific, antigenic fibrinogen
sequences be identified, generating antibodies to citrullinated peptides could prevent the immune
system from recognizing these sequences as foreign and lead to a reduction in overall
inflammatory burden in MS patients. Citrullination occurs as a result of PADs and it has been
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shown that inhibition of PAD activity prior to the onset or induction of mouse models of
neurodegeneration and autoimmunity can reverse citrullination and prevent disease activity (440).
Therefore, investigating PAD activity in pEV-injected EAE mice should be investigated to
determine if increased expression of these enzyme could be a causative agent in driving the
relapsing phenotype and, if so, whether therapeutic intervention can abolish the relapsing
phenotype observed. Further, analysis of PAD activity in the blood of healthy and MS patients
could be analyzed to determine if increased PAD activity correlates to disease exacerbation or as
a predicative diagnostic readout of a nascent relapse.
III. Concluding Statement
My thesis studies into astrocyte and plasma EVs have shed light on the potential role for
these vesicles in contributing to the initiation of disease, exacerbation of diseases, and as potential
diagnostic and therapeutic targets in MS. However, further research and studies, which have been
outlined, must be performed to better characterize these EVs before the scientific community can
accept the findings as impactful. I have a strong belief, though, that through innovative thinking
and elegant experiment design, many of these questions will be answered and further cement a
place for EVs in the pathology of MS and, hopefully, many other neurodegenerative diseases.
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Figure 5-1: Astrocyte EVs promote the differentiation and maturation of rOPCs in vitro.
rOPCs were treated with either constitutively released astrocyte-EVs or IL-1β stimulated
astrocyte-EVs and differentiation analyzed after 48 hours in vitro. There was a significant increase
in rOPC differentiation following constitutive astrocyte-EV treatment compared to OPC
maintenance media. IL-1β stimulated astrocyte-EVs significantly inhibited OPC differentiation
compared to constitutive astrocyte-EVs and no difference was observed compared to OPC
maintenance media. Significance as indicated where: **P < 0.01 and ****P < 0.0001, one-way
ANOVA with Tukey’s multiple comparison test. Values are expressed as mean ± SEM.
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Fig. 5-2: IVIS imaging of DiR-labeled EVs injected into naïve and MOG-EAE mice. Blood
plasma EVs were stained with the lipophilic tracer DiR and I.V. injected into naïve or EAE animals
at peak clinical illness. Imaging of organs three hours following injection showed EVs
preferentially trafficked to the liver and brain in both naïve (left) and MOG-EAE mice (right).
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